Wilson disease is a rare autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene encoding a copper-transporting P-type ATPase. ATP7B dysfunction impairs biliary copper excretion and ceruloplasmin biosynthesis, leading to toxic copper accumulation primarily in the liver and brain, with secondary involvement of the kidneys, eyes, heart, muscles, and bones. Clinical presentations range from asymptomatic liver disease to fulminant hepatic failure, chronic hepatitis, cirrhosis, and diverse neuropsychiatric manifestations including dystonia, tremor, dysarthria, depression, and psychosis. Kayser-Fleischer corneal rings are characteristic, and hemolytic anemia can accompany acute hepatic presentations. Diagnosis relies on the modified Leipzig Scoring System integrating serum ceruloplasmin, urinary copper, hepatic copper content, and genetic testing. Treatment with copper chelators (D-penicillamine, trientine) and zinc salts can prevent disease progression when initiated early; liver transplantation is curative for end-stage hepatic disease.
Ask a research question about Wilson Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Wilson Disease:
name: Wilson Disease
creation_date: '2025-12-19T14:27:56Z'
updated_date: '2026-05-21T16:57:45Z'
category: Genetic
description: >
Wilson disease is a rare autosomal recessive disorder of copper metabolism caused by mutations
in the ATP7B gene encoding a copper-transporting P-type ATPase. ATP7B dysfunction impairs
biliary copper excretion and ceruloplasmin biosynthesis, leading to toxic copper accumulation
primarily in the liver and brain, with secondary involvement of the kidneys, eyes, heart,
muscles, and bones. Clinical presentations range from asymptomatic liver disease to fulminant
hepatic failure, chronic hepatitis, cirrhosis, and diverse neuropsychiatric manifestations
including dystonia, tremor, dysarthria, depression, and psychosis. Kayser-Fleischer corneal
rings are characteristic, and hemolytic anemia can accompany acute hepatic presentations. Diagnosis relies on
the modified Leipzig Scoring System integrating serum ceruloplasmin, urinary copper, hepatic
copper content, and genetic testing. Treatment with copper chelators (D-penicillamine, trientine)
and zinc salts can prevent disease progression when initiated early; liver transplantation is
curative for end-stage hepatic disease.
disease_term:
preferred_term: Wilson disease
term:
id: MONDO:0010200
label: Wilson disease
notes: >-
ORPHA:905 cross-references Wilson disease to MONDO:0010200 with an Exact mapping
and also lists Genetic and Rare Diseases Information Center entry 7893,
ICD-10:E83.0, ICD-11:5C64.00, MeSH:D006527, MedDRA:10019819, OMIM:277900,
and UMLS:C0019202.
synonyms:
- hepatolenticular degeneration
- WD
parents:
- Metabolic Disease
- Liver Disease
inheritance:
- name: Autosomal Recessive
inheritance_term:
preferred_term: Autosomal recessive inheritance
term:
id: HP:0000007
label: Autosomal recessive inheritance
evidence:
- reference: PMID:37741465
reference_title: "Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease."
supports: SUPPORT
snippet: "Inactivating mutations of the copper-transporting P-type ATPase, ATP7B, result in Wilson's disease, an autosomal recessive disorder"
explanation: Directly states autosomal recessive inheritance for Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Autosomal recessive"
explanation: Orphanet's structured inheritance section independently classifies Wilson disease as autosomal recessive.
prevalence:
- population: Global clinically diagnosed populations
percentage: 1 in 30,000
notes: >-
Clinical prevalence estimates for Wilson disease are typically around 1 in
30,000, although national registry estimates can be lower or higher
depending on ascertainment intensity and diagnostic capture.
evidence:
- reference: PMID:23518715
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Using this most conservative approach, the calculated frequency of individuals predicted to carry two mutant pathogenic ATP7B alleles is 1:7026 and thus still considerably higher than the typically reported prevalence of Wilson's disease of 1:30 000 (P = 0.00093)."
explanation: This paper explicitly cites the conventional clinically recognized prevalence of Wilson disease as about 1 in 30,000.
- reference: PMID:38565173
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The average age- and sex-adjusted prevalence and incidence of WD between 2010 and 2020 were 3.06/100,000 and 0.11/100,000, respectively."
explanation: A contemporary national claims analysis shows a clinically ascertained prevalence of 3.06 per 100,000 in Korea, consistent with rare-disease prevalence.
- population: Orphanet worldwide and regional estimates
percentage: 1-9 per 100,000 worldwide; 1-5 per 10,000 in China, Japan, and some specific populations
notes: >-
Orphanet records both worldwide point/prevalence-at-birth estimates and higher
regional or specific-population ranges, indicating geographic variation in
clinically recognized Wilson disease frequency.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-9 / 100 000 | Worldwide | Point prevalence | PMID:31449670"
explanation: Orphanet's epidemiology table gives a worldwide point-prevalence range for Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:31449670"
explanation: Orphanet separately records the same worldwide range as prevalence at birth.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-5 / 10 000 | China | Point prevalence | PMID:20301685"
explanation: Orphanet records a higher point-prevalence range for China, supporting regional variation.
- population: Global population sequencing datasets
percentage: 13.9 per 100,000
notes: >-
Sequencing-based studies estimate a substantially higher genetic prevalence
than clinically diagnosed prevalence, suggesting underdiagnosis and/or
reduced penetrance in some ATP7B genotype carriers.
evidence:
- reference: PMID:30254379
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Based on these, the genetic prevalence of WD was 13.9 per 100,000 (95% CI: 12.9-14.9), or 1 per 7194."
explanation: Meta-analysis of ATP7B sequencing data provides a global genetic prevalence estimate for Wilson disease.
- reference: PMID:23518715
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Using this most conservative approach, the calculated frequency of individuals predicted to carry two mutant pathogenic ATP7B alleles is 1:7026 and thus still considerably higher than the typically reported prevalence of Wilson's disease of 1:30 000 (P = 0.00093)."
explanation: Independent UK sequencing data supports a similarly elevated genetic prevalence estimate relative to diagnosed cases.
progression:
- phase: Onset
age_range: Childhood to elderly adulthood
notes: >-
Orphanet lists Wilson disease onset categories spanning childhood, adolescence,
adulthood, and elderly onset.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Childhood"
explanation: Orphanet records childhood as an age-of-onset category for Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Adolescent"
explanation: Orphanet records adolescent onset as part of the Wilson disease natural history.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Adult"
explanation: Orphanet records adult onset as part of the Wilson disease natural history.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Elderly"
explanation: Orphanet records elderly onset as a possible Wilson disease natural-history category.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_atp7b_copper_retention
hypothesis_label: Canonical ATP7B Copper-Retention Model
status: CANONICAL
description: >
ATP7B loss impairs biliary copper excretion and ceruloplasmin loading,
causing hepatic copper retention with secondary extrahepatic toxicity.
notes: >-
Retained as the initiating canonical model. Population data indicate that
ATP7B genotype is necessary but not sufficient to predict clinical expression;
penetrance, residual function, and modifier mechanisms remain important
unresolved qualifiers.
evidence:
- reference: PMID:12426114
reference_title: "Molecular mechanism of copper transport in Wilson disease."
supports: SUPPORT
snippet: "The Wilson disease protein is a putative copper-transporting P-type ATPase, ATP7B, whose malfunction results in the toxic accumulation of copper in the liver and brain, causing the hepatic and/or neurological symptoms accompanying this disease."
explanation: Supports ATP7B dysfunction as the core mechanism that links copper retention to hepatic and neurologic disease.
- reference: PMID:39322449
reference_title: "Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "The widespread mutations p.Met645Arg and p.Gly869Arg show low penetrance."
explanation: >
Qualifies the canonical ATP7B model by showing that some frequent ATP7B
genotypes have reduced clinical penetrance and therefore require modifiers
beyond the initiating copper-retention defect.
- hypothesis_group_id: oxidative_mitochondrial_injury_model
hypothesis_label: Oxidative-Mitochondrial Injury Model
status: CANONICAL
description: >
Copper excess drives reactive oxygen species, lipid peroxidation,
mitochondrial injury, and impaired bioenergetics, producing hepatocellular
damage. Cuproptosis and ferroptosis operate as additional mitochondrial and
lipid-peroxidation amplifiers rather than replacements for this canonical
oxidative injury model.
notes: >-
Retained as CANONICAL. The strongest update is not a status change, but a
broader multi-mechanism formulation in which oxidative mitochondrial injury
is the best-supported common pathway and cuproptosis/ferroptosis are
emerging pathway-specific contributors.
evidence:
- reference: PMID:15205951
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "Excess copper, however, induces free-radical reactions and lipid peroxidation."
explanation: Directly supports oxidative injury as a canonical downstream mechanism.
- reference: PMID:41480142
reference_title: "Mitochondrial dysfunction in Wilson disease: a systematic review and meta-analysis across human and animal models."
supports: SUPPORT
evidence_source: OTHER
snippet: "Across human and animal studies, hepatic mitochondria in WD exhibit copper accumulation, structural injury, impaired bioenergetics, oxidative stress, and mitochondrial genome loss."
explanation: >
Meta-analysis supports mitochondrial copper accumulation, oxidative stress,
structural injury, and impaired bioenergetics as a central pathogenic
feature across Wilson disease patients and models.
- hypothesis_group_id: neurodegenerative_movement_model
hypothesis_label: Neurodegenerative Movement Disorder Model
status: CANONICAL
description: >
Copper-related brain injury in motor control circuits drives dysarthria,
dystonia, parkinsonism, and related movement phenotypes. The model includes
irreversible neurodegeneration plus reversible functional, inflammatory, and
circuit-level dysfunction that can improve when copper exposure is reduced.
notes: >-
Retained as CANONICAL with a dual-mechanism qualifier: fixed structural
damage explains persistent late-stage deficits, while reversible circuit,
neurotransmitter, and inflammatory mechanisms explain substantial treatment
responsiveness.
evidence:
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "Wilson disease (WD) is a neurodegenerative disorder, which presents as a spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Supports neurodegeneration as a major explanatory framework for Wilson disease movement phenotypes.
- reference: PMID:36165286
reference_title: "Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Brain atrophy rate appears as a promising marker of neurodegeneration in Wilson's disease."
explanation: Longitudinal MRI evidence supports active neurodegeneration in neurological Wilson disease.
- reference: PMID:33590415
reference_title: "Toxic milk mice models of Wilson's disease."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "No changes were noted in the neurological and behavioral status of this strain despite the described toxic accumulation of copper and neuronal destruction in their brain."
explanation: >
Qualifies the simple neurodegeneration-only model by showing that copper
accumulation and neuronal destruction are not always sufficient for a
movement phenotype in toxic milk mouse models.
- hypothesis_group_id: cuproptosis_model
hypothesis_label: Copper-Dependent Cuproptosis Model
status: EMERGING
description: >
Beyond oxidative damage alone, copper may induce a distinct mitochondrial
cell-death program (cuproptosis) that amplifies hepatic tissue injury.
Evidence remains model-based, with human Wilson disease tissue validation
of lipoylated protein aggregation still lacking.
notes: >-
Retained as EMERGING. Current evidence supports cuproptosis as a hepatic
amplification layer within broader copper toxicity, not as an independent
dominant mechanism and not yet as a neurological Wilson disease mechanism.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: PARTIAL
snippet: "Many interesting disease details were published on the mechanistic steps, such as the generation of reactive oxygen species (ROS) and cuproptosis causing a copper dependent cell death."
explanation: Supports cuproptosis as a proposed emerging mechanistic layer in Wilson disease rather than a definitively established dominant pathway.
- reference: PMID:41230834
reference_title: "Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Cuproptosis markers (FDX1, DLST, DLAT, LIAS) were upregulated in both liver tissue"
explanation: >
ATP7B-knockout mouse liver tissue provides direct model-organism evidence
that cuproptosis-related markers are altered in Wilson disease contexts.
- reference: PMID:41230834
reference_title: "Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Copper exposure decreased cell viability and increased LDH release, exacerbated by Elesclomol and alleviated by Tetrathiomolybdate."
explanation: >
Copper-treated HepG2 cell data provide in vitro evidence that copper
exposure induces cell injury consistent with the cuproptosis hypothesis and
is modulated by cuproptosis-relevant copper handling.
- hypothesis_group_id: ferroptosis_superimposition_model
hypothesis_label: Iron-Related Ferroptosis Superimposition Model
status: EMERGING
description: >
Secondary hepatic iron deposition may superimpose iron-driven ferroptotic
injury on copper-mediated pathology in a subset of patients or disease
stages, but copper-driven lipid peroxidation and cuproptosis remain
important competing explanations.
notes: >-
Retained as EMERGING. The best-supported interpretation is a copper-iron
synergy or modifier model; ferroptosis-specific rescue and human
iron-stratified outcome data are still missing.
evidence:
- reference: PMID:39733327
reference_title: "Iron and Copper Liver Concentrations in Wilson Disease."
supports: PARTIAL
snippet: "13 (8%) patients aged 13 or older had a hepatic iron index >1.0 which may indicate secondary iron overload."
explanation: Directly supports that a subset of Wilson disease patients has secondary hepatic iron overload, which is a prerequisite for the ferroptosis hypothesis.
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: PARTIAL
snippet: "In the liver of patients with Wilson disease, also, increased iron deposits were found that may lead to iron-related ferroptosis responsible for phospholipid peroxidation within membranes of subcellular organelles"
explanation: Supports ferroptosis as an inferred downstream consequence of secondary hepatic iron deposition rather than a fully established mechanism in Wilson disease.
- reference: PMID:41966025
reference_title: "Quercetin alleviates liver injury in Wilson's disease by inhibiting ferroptosis."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "QUE treatment significantly alleviated liver injury, iron overload, oxidative stress, lipid peroxidation, and mitochondrial dysfunction."
explanation: >
Wilson disease model data support ferroptosis-linked liver injury and show
that quercetin modifies iron overload, lipid peroxidation, mitochondrial
dysfunction, and hepatic injury, while still requiring human validation.
- hypothesis_group_id: liver_derived_neuroinflammation_model
hypothesis_label: Liver-Derived Neuroinflammation (Liver-Brain Axis) Model
status: EMERGING
description: >
Beyond direct brain copper deposition, hepatic copper toxicity and the
resulting liver inflammation may drive neurological manifestations through a
liver-brain crosstalk axis. In a genetically precise Atp7b R778L mouse
model, neurological and cognitive deficits with CNS cytokine elevation and
microglial activation developed without a detectable rise in brain copper,
and suppressing hepatic inflammation reversed the neurobehavioral deficits.
This positions liver-derived inflammatory signaling as a partly
copper-deposition-independent contributor to neurological Wilson disease.
notes: >-
Retained as EMERGING and complementary to the canonical neurodegenerative
movement model rather than a replacement. The strongest current evidence is
a single-genotype mouse model; the relative contribution of direct brain
copper toxicity versus liver-derived inflammatory mediators in humans, and
across genotypes and disease stages, remains unresolved.
evidence:
- reference: PMID:39334421
reference_title: "Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "inhibition of hepatic inflammation with PJ34 or siNfkb markedly alleviated the deficiencies in cognitive performance and improved locomotor activity in R778L mice"
explanation: >
Suppressing hepatic inflammation rescued cognitive and locomotor deficits
in the R778L Wilson disease model, supporting a causal liver-to-brain
inflammatory axis underlying neurological manifestations.
- reference: PMID:39334421
reference_title: "Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "the Cu2+ levels in the brain tissue of R778L mice did not differ significantly from those of wild-type mice"
explanation: >
Absence of a measurable brain copper increase despite neurological
deficits qualifies the direct-brain-copper model and motivates a
liver-derived inflammatory mechanism, while leaving human validation open.
pathophysiology:
- name: ATP7B Copper-Trafficking Defect
description: >
Loss of hepatocyte ATP7B copper-trafficking function is the shared upstream
defect that impairs both copper excretion into bile and copper incorporation
into apoceruloplasmin in the secretory pathway.
gene:
preferred_term: ATP7B
term:
id: hgnc:870
label: ATP7B
molecular_functions:
- preferred_term: P-type monovalent copper transporter activity
term:
id: GO:0140581
label: P-type monovalent copper transporter activity
biological_processes:
- preferred_term: copper ion transport
term:
id: GO:0006825
label: copper ion transport
cellular_components:
- preferred_term: Golgi apparatus
term:
id: GO:0005794
label: Golgi apparatus
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
evidence:
- reference: PMID:16382340
reference_title: "Wilson disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The basic defect is an impaired trafficking of copper in hepatocytes."
explanation: >
This clinical review identifies impaired hepatocyte copper trafficking as
the core upstream Wilson disease defect.
downstream:
- target: Impaired Biliary Copper Excretion
description: >
ATP7B copper trafficking normally supports hepatocyte copper movement into
the bile excretion pathway.
causal_link_type: DIRECT
evidence:
- reference: PMID:16382340
reference_title: "Wilson disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >
ATP7B is the gene product of the WD gene located on chromosome 13 and
resides in hepatocytes in the trans-Golgi network, transporting copper
into the secretory pathway for incorporation into apoceruloplasmin and
excretion into the bile.
explanation: >
The review directly states that hepatocyte ATP7B transports copper
through the secretory pathway for biliary excretion.
- target: Impaired Ceruloplasmin Loading
description: >
The same ATP7B secretory-pathway trafficking defect prevents copper
incorporation into apoceruloplasmin.
causal_link_type: DIRECT
evidence:
- reference: PMID:16382340
reference_title: "Wilson disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >
ATP7B is the gene product of the WD gene located on chromosome 13 and
resides in hepatocytes in the trans-Golgi network, transporting copper
into the secretory pathway for incorporation into apoceruloplasmin and
excretion into the bile.
explanation: >
The same review explicitly links hepatocyte ATP7B copper transport to
apoceruloplasmin copper incorporation.
- name: Impaired Biliary Copper Excretion
description: >
ATP7B mutations impair copper excretion into bile. ATP7B normally resides in
the trans-Golgi network and traffics to the bile canalicular membrane when
intracellular copper is elevated. Loss of ATP7B function prevents this
copper export pathway.
gene:
preferred_term: ATP7B
term:
id: hgnc:870
label: ATP7B
molecular_functions:
- preferred_term: P-type monovalent copper transporter activity
term:
id: GO:0140581
label: P-type monovalent copper transporter activity
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Copper accumulation in the liver is due to impaired biliary excretion of copper caused by the inheritable malfunctioning or missing ATP7B protein."
explanation: Confirms that impaired biliary copper excretion is the primary defect caused by ATP7B dysfunction.
- reference: PMID:16382340
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "ATP7B is the gene product of the WD gene located on chromosome 13 and resides in hepatocytes in the trans-Golgi network, transporting copper into the secretory pathway for incorporation into apoceruloplasmin and excretion into the bile."
explanation: Supports ATP7B localization to the trans-Golgi network with biliary excretion function.
- reference: PMID:18395099
reference_title: "ATP7B copper-regulated traffic and association with the tight junctions: copper excretion into the bile."
supports: SUPPORT
snippet: "Copper excess provokes a massive download of the ATP7B retained in the trans-Golgi network into the bile canalicular membrane."
explanation: Demonstrates copper-stimulated ATP7B trafficking to the canalicular membrane.
biological_processes:
- preferred_term: copper ion transport
term:
id: GO:0006825
label: copper ion transport
cellular_components:
- preferred_term: Golgi apparatus
term:
id: GO:0005794
label: Golgi apparatus
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
downstream:
- target: Hepatic Copper Accumulation
description: Loss of biliary copper excretion leads to progressive copper retention in hepatocytes.
causal_link_type: DIRECT
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Copper accumulation in the liver is due to impaired biliary excretion of copper caused by the inheritable malfunctioning or missing ATP7B protein.
explanation: Directly supports impaired biliary copper excretion as the cause of hepatic copper accumulation.
- name: Impaired Ceruloplasmin Loading
description: >
ATP7B normally loads copper into apoceruloplasmin in the trans-Golgi network.
Loss of ATP7B function results in secretion of copper-free apoceruloplasmin,
which is rapidly degraded, leading to the characteristic low serum
ceruloplasmin levels.
gene:
preferred_term: ATP7B
term:
id: hgnc:870
label: ATP7B
molecular_functions:
- preferred_term: P-type monovalent copper transporter activity
term:
id: GO:0140581
label: P-type monovalent copper transporter activity
evidence:
- reference: PMID:16382340
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "ATP7B is the gene product of the WD gene located on chromosome 13 and resides in hepatocytes in the trans-Golgi network, transporting copper into the secretory pathway for incorporation into apoceruloplasmin and excretion into the bile."
explanation: Supports that ATP7B loads copper into apoceruloplasmin in the secretory pathway.
biological_processes:
- preferred_term: copper ion homeostasis
term:
id: GO:0055070
label: copper ion homeostasis
downstream:
- target: Ceruloplasmin
description: Failure to load copper into apoceruloplasmin leads to low circulating ceruloplasmin.
causal_link_type: DIRECT
evidence:
- reference: PMID:16382340
reference_title: Wilson disease.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: ATP7B is the gene product of the WD gene located on chromosome 13 and resides in hepatocytes in the trans-Golgi network, transporting copper into the secretory pathway for incorporation into apoceruloplasmin and excretion into the bile.
explanation: Links ATP7B secretory-pathway copper transport to apoceruloplasmin loading, explaining low circulating ceruloplasmin when loading fails.
- name: Hepatic Copper Accumulation
description: >
Impaired biliary excretion causes progressive copper retention in
hepatocytes. When hepatic storage capacity is exceeded, copper is
released into the circulation.
evidence:
- reference: PMID:16382340
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "Wilson disease (WD) is an autosomal recessive inherited disorder of copper metabolism, resulting in pathological accumulation of copper in many organs and tissues."
explanation: Supports multi-organ copper accumulation in Wilson disease.
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury."
explanation: Confirms hepatic copper overflow into systemic circulation.
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
locations:
- preferred_term: liver
term:
id: UBERON:0002107
label: liver
downstream:
- target: Hepatocyte Injury
description: Copper overload in hepatocytes drives oxidative stress and cell death.
causal_link_type: DIRECT
evidence:
- reference: PMID:24517326
reference_title: Pathological mitochondrial copper overload in livers of Wilson's disease patients and related animal models.
supports: SUPPORT
evidence_source: OTHER
snippet: On the contrary, however, when copper is massively deposited in mitochondria, severe structural and respiratory impairments are observed upon disease progression. This provokes reactive oxygen species and consequently causes the mitochondrial membranes to disintegrate, which triggers hepatocyte death.
explanation: Shows that pathological hepatic mitochondrial copper deposition drives respiratory injury, ROS, membrane disintegration, and hepatocyte death.
- target: Systemic Copper Distribution
description: Overflow of copper from the liver enters the circulation and deposits in extrahepatic organs.
causal_link_type: DIRECT
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports release of toxic copper from liver cells into circulation with deposition and injury in extrahepatic organs.
- target: Hepatic Copper
description: Retained hepatic copper becomes measurably increased on liver biopsy.
causal_link_type: DIRECT
evidence:
- reference: PMID:15205951
reference_title: Wilson disease.
supports: SUPPORT
evidence_source: OTHER
snippet: The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content.
explanation: Identifies increased hepatic copper content as the measurable biochemical readout of hepatic copper accumulation.
- name: Systemic Copper Distribution
description: >
When hepatic copper storage capacity is exceeded, free copper enters
the circulation and deposits in the brain, kidneys, eyes, heart,
muscles, and bones, causing multi-organ injury.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain"
explanation: Explains the pathophysiology of systemic copper distribution from hepatic overflow.
- reference: PMID:25002079
reference_title: "A study of oxidative stress, cytokines and glutamate in Wilson disease and their asymptomatic siblings."
supports: PARTIAL
snippet: "Free copper in Wilson disease (WD) is toxic and may reduce antioxidant, increase oxidative stress marker and thereby cytokine release and excitotoxic injury, but there is paucity of studies in humans."
explanation: Supports toxic effects of circulating free copper causing oxidative stress and excitotoxic injury.
downstream:
- target: Neurodegeneration
description: Copper deposition in the basal ganglia and other brain regions causes neuronal injury.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433113
reference_title: 'Wilson disease: brain pathology.'
supports: SUPPORT
evidence_source: OTHER
snippet: In Wilson disease (WD), brain cellular damage is thought to be due to copper deposition. Striatal lesions are the most characteristic lesions found in the brain of patients with neurologic symptoms, as emphasized in the initial reports of S.A.K. Wilson.
explanation: Supports copper deposition as a driver of brain cellular damage and characteristic neurologic lesions.
- target: Non-Ceruloplasmin-Bound Serum Copper
description: Overflow of hepatocellular copper raises the circulating free copper fraction.
causal_link_type: DIRECT
evidence:
- reference: PMID:16709660
reference_title: "Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Diagnostic criteria for non-caeruloplasmin-bound serum copper, serum caeruloplasmin, 24-h urinary copper excretion, liver copper content, presence of Kayser-Fleischer rings and histological signs of chronic liver damage were reached in 86.6%, 88.2%, 87.1%, 92.7%, 66.3% and 73% of patients, respectively.
explanation: Supports non-ceruloplasmin-bound serum copper as a diagnostic biochemical manifestation of systemic Wilson copper dysregulation.
- target: 24-Hour Urinary Copper
description: Increased circulating free copper drives elevated urinary copper excretion.
causal_link_type: DIRECT
evidence:
- reference: PMID:15205951
reference_title: Wilson disease.
supports: SUPPORT
evidence_source: OTHER
snippet: The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content.
explanation: Supports increased urinary copper excretion as a biochemical readout of increased circulating/free copper burden.
- target: Kayser-Fleischer Rings
description: Copper deposition in Descemet membrane produces Kayser-Fleischer corneal rings.
causal_link_type: DIRECT
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports systemic copper redistribution causing organ injury and lists kayser-fleischer rings among Wilson disease clinical features.
- target: Renal Tubular Dysfunction
description: Copper deposition in the kidneys contributes to renal tubular injury and dysfunction.
causal_link_type: DIRECT
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports systemic copper redistribution causing organ injury and lists renal tubular dysfunction among Wilson disease clinical features.
- target: Cardiomyopathy
description: Cardiac copper deposition contributes to myocardial injury and cardiomyopathy.
causal_link_type: DIRECT
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports systemic copper redistribution causing organ injury and lists cardiomyopathy among Wilson disease clinical features.
- target: Heart Failure
description: Copper-mediated cardiac injury can progress to clinical heart failure.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Copper-related cardiomyopathy and cardiac remodeling.
evidence:
- reference: PMID:28947309
reference_title: "Wilson's Disease and Cardiac Myopathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: patients with Wilson's disease had a 55% higher risk of incident HF (HR 1.55, 95% CI 1.41 to 1.71, p <0.0001)
explanation: Population-level clinical data support increased heart-failure risk in Wilson disease, consistent with downstream cardiac involvement from copper dysregulation.
- target: Cardiac Arrhythmia
description: Copper-mediated cardiac involvement increases the risk of clinically significant arrhythmias.
causal_link_type: DIRECT
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports systemic copper redistribution causing organ injury and lists cardiac arrhythmia among Wilson disease clinical features.
- target: Osteopenia
description: Extrahepatic copper toxicity contributes to reduced bone mineral density.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Renal tubular dysfunction, altered mineral balance, and reduced bone mineral density.
evidence:
- reference: PMID:29110062
reference_title: "Osteoporosis and bone mineral density in patients with Wilson's disease: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The pooled prevalencerates of osteopenia and osteoporosis in WD patients were 36.5%"
explanation: Meta-analysis supports osteopenia and osteoporosis as Wilson disease bone manifestations downstream of systemic disease.
- target: Osteoporosis
description: Chronic extrahepatic copper toxicity contributes to pathologic bone loss in a subset of patients.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Renal tubular dysfunction, altered mineral balance, and reduced bone mineral density.
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports systemic copper redistribution causing organ injury and lists osteoporosis among Wilson disease clinical features.
- target: Arthralgia
description: Musculoskeletal copper deposition and bone disease contribute to arthralgia.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Wilson disease osteoarticular involvement and bone-density abnormalities.
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports systemic copper redistribution causing organ injury and lists arthralgia among Wilson disease clinical features.
- target: Sunflower Cataract
description: Copper deposition in ocular tissues can produce the rare sunflower cataract phenotype.
causal_link_type: DIRECT
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:6000642 | Sunflower cataract | Very rare (<4-1%)
explanation: Orphanet records sunflower cataract as a Wilson disease phenotype; the edge places this feature downstream of systemic copper disease.
- target: Abnormality Of The Menstrual Cycle
description: Systemic copper disease and chronic hepatic dysfunction can disrupt reproductive cycling through incompletely resolved endocrine intermediates.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0000140 | Abnormality of the menstrual cycle | Very frequent (99-80%)
explanation: Orphanet records abnormality of the menstrual cycle as a Wilson disease phenotype; the edge places this feature downstream of systemic copper disease.
- target: Bone Pain
description: Copper-related skeletal disease and low bone mineral density can manifest with bone pain.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Osteopenia, osteoporosis, osteomalacia, and renal tubular mineral dysregulation.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0002653 | Bone pain | Very frequent (99-80%)
explanation: Orphanet records bone pain as a Wilson disease phenotype; the edge places this feature downstream of systemic copper disease.
- target: Arthritis
description: Systemic copper-related musculoskeletal involvement includes arthritic manifestations in a subset of patients.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Musculoskeletal copper toxicity, arthropathy, and low bone-density complications.
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Supports systemic copper redistribution causing organ injury and lists arthritis among Wilson disease clinical features.
- target: Joint Swelling
description: Musculoskeletal involvement can present with inflammatory or arthropathic joint swelling.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Wilson disease arthropathy and related skeletal inflammation.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001386 | Joint swelling | Very frequent (99-80%)
explanation: Orphanet records joint swelling as a Wilson disease phenotype; the edge places this feature downstream of systemic copper disease.
- target: Pathologic Fracture
description: Chronic skeletal involvement with osteopenia or osteoporosis increases vulnerability to pathologic fracture.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Osteopenia and osteoporosis.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0002756 | Pathologic fracture | Very frequent (99-80%)
explanation: Orphanet records pathologic fracture as a Wilson disease phenotype; the edge places this feature downstream of systemic copper disease.
- name: Hepatocyte Injury
description: >
Copper accumulation in hepatocytes causes oxidative stress, mitochondrial
dysfunction, impaired bioenergetics, and cell death. Severe injury can
manifest as hepatitis, jaundice, hepatomegaly, and acute liver failure.
Copper overload also activates autophagy and mitophagy-based mitochondrial
quality control responses, while cuproptosis and ferroptosis may amplify
injury in model systems and susceptible hepatic contexts.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Excess Cu2+ primarily leads to the generation of reactive oxygen species (ROS), as evidenced by early experimental studies exemplified with the detection of hydroxyl radical formation"
explanation: Demonstrates that excess copper generates ROS leading to oxidative stress and cellular injury.
- reference: PMID:24517326
reference_title: "Pathological mitochondrial copper overload in livers of Wilson's disease patients and related animal models."
supports: SUPPORT
snippet: "On the contrary, however, when copper is massively deposited in mitochondria, severe structural and respiratory impairments are observed upon disease progression. This provokes reactive oxygen species and consequently causes the mitochondrial membranes to disintegrate, which triggers hepatocyte death."
explanation: Supports mitochondrial dysfunction, ROS generation, and hepatocyte death with copper overload.
- reference: PMID:28433112
reference_title: "Wilson disease - liver pathology."
supports: SUPPORT
snippet: "Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis."
explanation: Supports progression from hepatic injury to fibrosis and cirrhosis.
- reference: PMID:30452922
reference_title: "Activation of Autophagy, Observed in Liver Tissues From Patients With Wilson Disease and From ATP7B-Deficient Animals, Protects Hepatocytes From Copper-Induced Apoptosis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ATP7B-deficient hepatocytes, such as in those in patients with WD, activate autophagy in response to copper overload to prevent copper-induced apoptosis."
explanation: Demonstrates that human Wilson disease hepatocytes activate autophagy as a protective response to copper overload.
- reference: PMID:30452922
reference_title: "Activation of Autophagy, Observed in Liver Tissues From Patients With Wilson Disease and From ATP7B-Deficient Animals, Protects Hepatocytes From Copper-Induced Apoptosis."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Hepatocytes in liver tissues from patients with WD and from Atp7b-/- mice and rats (but not controls) had multiple autophagosomes."
explanation: Atp7b-/- mice and rats confirm autophagosome accumulation in ATP7B-deficient hepatocytes, corroborating the human findings.
- reference: PMID:33360697
reference_title: "Exposure to copper induces mitochondria-mediated apoptosis by inhibiting mitophagy and the PINK1/parkin pathway in chicken (Gallus gallus) livers."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "In general, the results reveal that Cu exposure can cause mitophagy through the PINK1/Parkin pathway in chicken livers, and that mitophagy might attenuate Cu-induced mitochondrial apoptosis."
explanation: Shows copper-induced mitophagy in chicken liver tissue (non-standard model), supporting mitochondrial quality control responses to copper overload.
- reference: PMID:41480142
reference_title: "Mitochondrial dysfunction in Wilson disease: a systematic review and meta-analysis across human and animal models."
supports: SUPPORT
evidence_source: OTHER
snippet: "Mitochondrial dysfunction arises early and worsens with progression, highlighting it as a central pathogenic feature and therapeutic target."
explanation: >
Systematic review and meta-analysis support mitochondrial dysfunction as
an early, progressive, central feature of Wilson disease liver injury.
- reference: PMID:35477108
reference_title: "Liver injury in Wilson's disease: An immunohistochemical study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Negligible COX4-1 and low COX2 expression in liver specimens may serve as markers of inner mitochondrial membrane injury in treated patients with WD and early stages of liver fibrosis."
explanation: Human liver biopsy immunohistochemistry supports inner mitochondrial membrane injury in Wilson disease.
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
locations:
- preferred_term: liver
term:
id: UBERON:0002107
label: liver
biological_processes:
- preferred_term: response to oxidative stress
term:
id: GO:0006979
label: response to oxidative stress
- preferred_term: mitophagy
term:
id: GO:0000423
label: mitophagy
downstream:
- target: Hepatic Stellate Cell Activation
description: Injured hepatocytes activate pro-fibrotic stellate-cell responses in the liver.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Copper-triggered TGF-beta/Smad and NF-kappaB signaling.
evidence:
- reference: PMID:41006805
reference_title: "The pathogenesis of liver fibrosis in Wilson's disease: hepatocyte injury and regulation mediated by copper metabolism dysregulation."
supports: SUPPORT
evidence_source: OTHER
snippet: Copper ions also activate signaling pathways such as the TGF-β1/Smad and NF-κB pathways, which stimulate hepatic stellate cells and promote their transdifferentiation into collagen-secreting myofibroblasts
explanation: Supports copper-triggered profibrotic signaling that stimulates hepatic stellate-cell activation.
- target: Neurodegeneration
description: >
Copper-driven hepatic inflammation can drive neuroinflammation and
neurological deficits through a liver-brain crosstalk axis, partly
independent of direct brain copper deposition.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Hepatic inflammation and circulating inflammatory cytokines signaling to the CNS (liver-brain axis).
- CNS microglial activation and inflammatory cytokine elevation.
evidence:
- reference: PMID:39334421
reference_title: "Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "inhibition of hepatic inflammation with PJ34 or siNfkb markedly alleviated the deficiencies in cognitive performance and improved locomotor activity in R778L mice"
explanation: >
Reversal of neurobehavioral deficits by suppressing hepatic inflammation
supports a liver-injury-to-neurodegeneration edge mediated by
inflammation rather than solely by direct brain copper accumulation.
- target: Hepatitis
description: Hepatocellular oxidative injury and inflammation manifest clinically as hepatitis.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433112
reference_title: Wilson disease - liver pathology.
supports: SUPPORT
evidence_source: OTHER
snippet: The liver in Wilson disease may demonstrate a wide range of damage patterns. Some patients may present almost no detectable microscopic pathology, while others display lesions consistent with fulminant hepatitis or acute liver failure. Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis. Additional findings include liver cell degeneration and ballooning, Mallory hyaline bodies, liver cell necrosis, and glycogenation of periportal hepatocytic nuclei.
explanation: Supports Wilson disease hepatocellular injury patterns that include the liver pathology represented by hepatitis.
- target: Hepatomegaly
description: Hepatocyte swelling and inflammatory liver injury can produce hepatomegaly.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Hepatic inflammation, cell swelling, and organ enlargement.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0002240 | Hepatomegaly | Very frequent (99-80%)
explanation: Orphanet records hepatomegaly as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- target: Jaundice
description: Acute hepatocellular dysfunction impairs bilirubin handling and can produce jaundice.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Hepatocellular dysfunction and impaired bilirubin handling.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0000952 | Jaundice | Very frequent (99-80%)
explanation: Orphanet records jaundice as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- target: Acute Hepatic Failure
description: Severe hepatocyte death can precipitate fulminant hepatic failure.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433112
reference_title: Wilson disease - liver pathology.
supports: SUPPORT
evidence_source: OTHER
snippet: The liver in Wilson disease may demonstrate a wide range of damage patterns. Some patients may present almost no detectable microscopic pathology, while others display lesions consistent with fulminant hepatitis or acute liver failure. Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis. Additional findings include liver cell degeneration and ballooning, Mallory hyaline bodies, liver cell necrosis, and glycogenation of periportal hepatocytic nuclei.
explanation: Wilson liver pathology includes fulminant hepatitis or acute liver failure, supporting acute failure as a severe hepatocyte-injury outcome.
- target: Hemolytic Anemia
description: Abrupt copper release from injured liver can trigger oxidant hemolysis.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Abrupt hepatic copper release and oxidant red-cell injury.
evidence:
- reference: PMID:24577547
reference_title: Acute hemolytic anemia as an initial presentation of Wilson disease in children.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Hemolytic anemia in WD occurs in up to 17% of patients at some point during their illness.
explanation: Supports hemolytic anemia as a recognized Wilson disease manifestation linked to hepatic copper injury and release.
- target: Vomiting
description: Acute hepatic decompensation can present with vomiting as part of the hepatic illness syndrome.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Acute hepatic illness and decompensation.
evidence:
- reference: PMID:29914392
reference_title: "Three novel mutations in the ATP7B gene of unrelated Vietnamese patients with Wilson disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: These patients had clinical features such as numbness of hands and feet, vomiting, insomnia, palsy, liver failure and Kayser-Fleischer (K-F) rings
explanation: Case-based clinical evidence supports vomiting as part of Wilson disease presentations that include liver failure.
- target: Cuproptosis
description: Proposed copper-dependent cell death pathways may amplify hepatocyte injury.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Copper overload, mitochondrial stress, and copper-dependent cell-death signaling.
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Many interesting disease details were published on the mechanistic steps, such as the generation of reactive oxygen species (ROS) and cuproptosis causing a copper dependent cell death.
explanation: Supports cuproptosis as a proposed copper-dependent cell-death layer that can amplify hepatic injury.
- target: Ferroptosis
description: Secondary iron deposition may superimpose ferroptotic injury in a subset of patients.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Secondary hepatic iron accumulation and lipid-peroxidation stress.
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: In the liver of patients with Wilson disease, also, increased iron deposits were found that may lead to iron-related ferroptosis responsible for phospholipid peroxidation within membranes of subcellular organelles
explanation: Supports iron-linked ferroptosis as an inferred secondary hepatic injury mechanism in Wilson disease contexts.
- target: Hepatic Steatosis
description: Copper-mediated hepatic injury commonly produces steatosis on liver biopsy.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433112
reference_title: Wilson disease - liver pathology.
supports: SUPPORT
evidence_source: OTHER
snippet: The liver in Wilson disease may demonstrate a wide range of damage patterns. Some patients may present almost no detectable microscopic pathology, while others display lesions consistent with fulminant hepatitis or acute liver failure. Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis. Additional findings include liver cell degeneration and ballooning, Mallory hyaline bodies, liver cell necrosis, and glycogenation of periportal hepatocytic nuclei.
explanation: Supports Wilson disease hepatocellular injury patterns that include the liver pathology represented by hepatic steatosis.
- target: Acute Hepatitis
description: Acute hepatocellular injury can present with an acute hepatitis phenotype.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433112
reference_title: Wilson disease - liver pathology.
supports: SUPPORT
evidence_source: OTHER
snippet: The liver in Wilson disease may demonstrate a wide range of damage patterns. Some patients may present almost no detectable microscopic pathology, while others display lesions consistent with fulminant hepatitis or acute liver failure. Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis. Additional findings include liver cell degeneration and ballooning, Mallory hyaline bodies, liver cell necrosis, and glycogenation of periportal hepatocytic nuclei.
explanation: Supports Wilson disease hepatocellular injury patterns that include the liver pathology represented by acute hepatitis.
- target: Elevated Circulating Hepatic Transaminase Concentration
description: Hepatocyte injury releases hepatic enzymes, producing elevated circulating transaminases.
causal_link_type: DIRECT
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0002910 | Elevated circulating hepatic transaminase concentration | Very frequent (99-80%)
explanation: Orphanet records elevated circulating hepatic transaminase concentration as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- target: Pruritus
description: Hepatic dysfunction and cholestatic intermediates can contribute to pruritus in Wilson disease.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Hepatic dysfunction and impaired bile-acid handling.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0000989 | Pruritus | Very frequent (99-80%)
explanation: Orphanet records pruritus as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- target: Abdominal Pain
description: Hepatic inflammation and decompensation can present with abdominal pain.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Hepatic inflammation, hepatomegaly, and acute liver decompensation.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0002027 | Abdominal pain | Occasional (29-5%)
explanation: Orphanet records abdominal pain as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- target: Failure To Thrive
description: Chronic hepatic disease and systemic illness can impair growth and weight gain.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Chronic liver disease, reduced intake, and systemic inflammatory illness.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001508 | Failure to thrive | Very frequent (99-80%)
explanation: Orphanet records failure to thrive as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- target: Weight Loss
description: Chronic hepatic disease and systemic illness can produce catabolic weight loss.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Chronic liver disease, reduced intake, and systemic inflammatory illness.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001824 | Weight loss | Very frequent (99-80%)
explanation: Orphanet records weight loss as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- target: Anemia
description: Hepatic decompensation can contribute to anemia through hemolytic and advanced-liver-disease intermediates.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Coombs-negative hemolysis and advanced liver disease.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001903 | Anemia | Very frequent (99-80%)
explanation: Orphanet records anemia as a Wilson disease phenotype; the edge models it as a clinical consequence of hepatic injury or decompensation.
- name: Hepatic Stellate Cell Activation
conforms_to: fibrotic_response#Mesenchymal Cell Activation
description: >
Copper-injured liver tissue activates pro-fibrotic signaling, including
TGF-beta and NF-kappaB pathways, which stimulate hepatic stellate cells to
transdifferentiate toward collagen-secreting myofibroblasts.
evidence:
- reference: PMID:41006805
reference_title: "The pathogenesis of liver fibrosis in Wilson's disease: hepatocyte injury and regulation mediated by copper metabolism dysregulation."
supports: SUPPORT
evidence_source: OTHER
snippet: "Copper ions also activate signaling pathways such as the TGF-β1/Smad and NF-κB pathways, which stimulate hepatic stellate cells and promote their transdifferentiation into collagen-secreting myofibroblasts"
explanation: Supports a distinct fibrogenic step in which copper-triggered signaling activates hepatic stellate cells and drives myofibroblast conversion.
cell_types:
- preferred_term: hepatic stellate cell
term:
id: CL:0000632
label: hepatic stellate cell
- preferred_term: myofibroblast cell
term:
id: CL:0000186
label: myofibroblast cell
locations:
- preferred_term: liver
term:
id: UBERON:0002107
label: liver
biological_processes:
- preferred_term: transforming growth factor beta receptor signaling pathway
term:
id: GO:0007179
label: transforming growth factor beta receptor signaling pathway
modifier: INCREASED
downstream:
- target: Excessive Hepatic ECM Deposition
description: Activated stellate cells and myofibroblasts drive excess extracellular matrix deposition.
causal_link_type: DIRECT
evidence:
- reference: PMID:41006805
reference_title: "The pathogenesis of liver fibrosis in Wilson's disease: hepatocyte injury and regulation mediated by copper metabolism dysregulation."
supports: SUPPORT
evidence_source: OTHER
snippet: collagen-secreting myofibroblasts, which then accelerate extracellular matrix deposition.
explanation: Directly supports extracellular-matrix deposition downstream of collagen-secreting myofibroblast conversion.
- name: Excessive Hepatic ECM Deposition
conforms_to: fibrotic_response#Excessive ECM Deposition
description: >
Collagen-secreting myofibroblasts deposit excessive extracellular matrix in
the liver, progressively distorting architecture and promoting cirrhosis.
evidence:
- reference: PMID:41006805
reference_title: "The pathogenesis of liver fibrosis in Wilson's disease: hepatocyte injury and regulation mediated by copper metabolism dysregulation."
supports: SUPPORT
evidence_source: OTHER
snippet: "collagen-secreting myofibroblasts, which then accelerate extracellular matrix deposition."
explanation: Supports extracellular matrix accumulation as the immediate downstream consequence of hepatic stellate-cell activation in Wilson disease liver fibrosis.
cell_types:
- preferred_term: myofibroblast cell
term:
id: CL:0000186
label: myofibroblast cell
locations:
- preferred_term: liver
term:
id: UBERON:0002107
label: liver
biological_processes:
- preferred_term: extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
modifier: INCREASED
- preferred_term: collagen biosynthetic process
term:
id: GO:0032964
label: collagen biosynthetic process
modifier: INCREASED
downstream:
- target: Cirrhosis
description: Progressive matrix deposition and architectural distortion manifest clinically as cirrhosis.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433112
reference_title: Wilson disease - liver pathology.
supports: SUPPORT
evidence_source: OTHER
snippet: The liver in Wilson disease may demonstrate a wide range of damage patterns. Some patients may present almost no detectable microscopic pathology, while others display lesions consistent with fulminant hepatitis or acute liver failure. Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis. Additional findings include liver cell degeneration and ballooning, Mallory hyaline bodies, liver cell necrosis, and glycogenation of periportal hepatocytic nuclei.
explanation: Supports fibrosis progressing to cirrhosis as the architectural consequence of excessive hepatic matrix deposition.
- target: Ascites
description: Cirrhotic architectural distortion can lead to portal hypertension and fluid accumulation as ascites.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Cirrhosis and portal hypertension.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001541 | Ascites | Occasional (29-5%)
explanation: Orphanet records ascites as a Wilson disease phenotype; the edge places it downstream of fibrotic/cirrhotic liver disease and portal-hypertension intermediates.
- target: Splenomegaly
description: Fibrotic progression to cirrhosis can produce portal-hypertension-associated splenomegaly.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Cirrhosis, portal hypertension, and congestive splenic enlargement.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001744 | Splenomegaly | Very frequent (99-80%)
explanation: Orphanet records splenomegaly as a Wilson disease phenotype; the edge places it downstream of fibrotic/cirrhotic liver disease and portal-hypertension intermediates.
- target: Thrombocytopenia
description: Cirrhosis and portal hypertension can cause hypersplenism-associated thrombocytopenia.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Cirrhosis, portal hypertension, splenomegaly, and hypersplenism.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001873 | Thrombocytopenia | Very frequent (99-80%)
explanation: Orphanet records thrombocytopenia as a Wilson disease phenotype; the edge places it downstream of fibrotic/cirrhotic liver disease and portal-hypertension intermediates.
- target: Bruising Susceptibility
description: Advanced hepatic fibrosis can contribute to bruising through synthetic dysfunction and thrombocytopenia.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Cirrhosis, impaired coagulation factor synthesis, and thrombocytopenia.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0000978 | Bruising susceptibility | Very frequent (99-80%)
explanation: Orphanet records bruising susceptibility as a Wilson disease phenotype; the edge places it downstream of fibrotic/cirrhotic liver disease and portal-hypertension intermediates.
- name: Neurodegeneration
description: >
Copper deposition is thought to drive brain cellular damage with
characteristic striatal/basal ganglia lesions. Longitudinal atrophy data
support active neurodegeneration, while reactive astrogliosis and microglial
activation with increased CNS inflammatory cytokines indicate
neuroinflammation contributing to movement and psychiatric symptoms.
evidence:
- reference: PMID:28433113
reference_title: "Wilson disease: brain pathology."
supports: SUPPORT
snippet: "In Wilson disease (WD), brain cellular damage is thought to be due to copper deposition. Striatal lesions are the most characteristic lesions found in the brain of patients with neurologic symptoms, as emphasized in the initial reports of S.A.K. Wilson."
explanation: Supports copper deposition driving brain damage with characteristic striatal lesions.
- reference: PMID:31179301
reference_title: "Neurologic impairment in Wilson disease."
supports: SUPPORT
snippet: "Most severe neuropathologic abnormalities, including tissue rarefaction, reactive astrogliosis, myelin palor, and presence of iron-laden macrophages, are typically present in the putamen while other basal ganglia, thalami, and brainstem are usually less affected."
explanation: Supports reactive astrogliosis and basal ganglia/putamen involvement.
- reference: PMID:39334421
reference_title: "Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "At 3-5 months of age, these mice started to display neurological deficits in motor coordination and cognitive dysfunction, accompanied by increased expression of inflammatory cytokines in the central nervous system. Microglia in the striatum and cortex exhibit significant activation, shorter processes, and decreased branch points."
explanation: Demonstrates CNS inflammatory cytokines and microglial activation in a Wilson disease mouse model.
- reference: PMID:36165286
reference_title: "Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The annualized atrophy rate was significantly greater in patients with the neurological presentation than in other patients (P = 0.001)."
explanation: Longitudinal MRI evidence supports accelerated brain atrophy in neurological Wilson disease.
- reference: PMID:39233127
reference_title: "Topographical metal burden correlates with brain atrophy and clinical severity in Wilson's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "magnetic susceptibility values were increased in WD patients compared with controls, including caudate nucleus, putamen, globus pallidus, and substantia nigra (all p < 0.01)."
explanation: Human QSM-MRI evidence links topographic brain metal burden to basal ganglia involvement in Wilson disease.
cell_types:
- preferred_term: astrocyte
term:
id: CL:0000127
label: astrocyte
- preferred_term: microglial cell
term:
id: CL:0000129
label: microglial cell
locations:
- preferred_term: collection of basal ganglia
term:
id: UBERON:0010011
label: collection of basal ganglia
- preferred_term: putamen
term:
id: UBERON:0001874
label: putamen
biological_processes:
- preferred_term: neuron apoptotic process
term:
id: GO:0051402
label: neuron apoptotic process
- preferred_term: neuroinflammatory response
term:
id: GO:0150076
label: neuroinflammatory response
modifier: INCREASED
- preferred_term: microglial cell activation
term:
id: GO:0001774
label: microglial cell activation
modifier: INCREASED
downstream:
- target: Tremor
description: Basal ganglia and cerebellar circuit injury contributes to tremor.
causal_link_type: DIRECT
evidence:
- reference: PMID:33474589
reference_title: "Neurological features and outcomes of Wilson's disease: a single-center experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: most common neurological manifestation was dystonia, followed by tremor and parkinsonism.
explanation: Clinical neurological Wilson disease data support tremor as a common manifestation of neurologic involvement.
- target: Dystonia
description: Striatal injury disrupts motor circuit output and contributes to dystonia.
causal_link_type: DIRECT
evidence:
- reference: PMID:33474589
reference_title: "Neurological features and outcomes of Wilson's disease: a single-center experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: most common neurological manifestation was dystonia, followed by tremor and parkinsonism.
explanation: Clinical neurological Wilson disease data support dystonia as a common manifestation of neurologic involvement.
- target: Parkinsonism
description: Basal ganglia dysfunction can manifest clinically as parkinsonism.
causal_link_type: DIRECT
evidence:
- reference: PMID:33474589
reference_title: "Neurological features and outcomes of Wilson's disease: a single-center experience."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: most common neurological manifestation was dystonia, followed by tremor and parkinsonism.
explanation: Clinical neurological Wilson disease data support parkinsonism as a common manifestation of neurologic involvement.
- target: Bradykinesia
description: Extrapyramidal circuit dysfunction contributes to bradykinesia.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433096
reference_title: 'Wilson disease: neurologic features.'
supports: SUPPORT
evidence_source: OTHER
snippet: Wilson disease (WD) is a neurodegenerative disorder, which presents as a spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia
explanation: Supports bradykinesia as part of the neurologic manifestation spectrum of Wilson disease neurodegeneration.
- target: Rigidity
description: Extrapyramidal circuit dysfunction contributes to rigidity.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433096
reference_title: 'Wilson disease: neurologic features.'
supports: SUPPORT
evidence_source: OTHER
snippet: Wilson disease (WD) is a neurodegenerative disorder, which presents as a spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia
explanation: Supports rigidity as part of the neurologic manifestation spectrum of Wilson disease neurodegeneration.
- target: Chorea
description: Basal ganglia injury can produce choreiform hyperkinesia.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433096
reference_title: 'Wilson disease: neurologic features.'
supports: SUPPORT
evidence_source: OTHER
snippet: Wilson disease (WD) is a neurodegenerative disorder, which presents as a spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia
explanation: Supports chorea as part of the neurologic manifestation spectrum of Wilson disease neurodegeneration.
- target: Dysarthria
description: Motor network injury affecting bulbar and extrapyramidal function contributes to dysarthria.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433096
reference_title: 'Wilson disease: neurologic features.'
supports: SUPPORT
evidence_source: OTHER
snippet: Wilson disease (WD) is a neurodegenerative disorder, which presents as a spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia
explanation: Supports dysarthria as part of the neurologic manifestation spectrum of Wilson disease neurodegeneration.
- target: Ataxia
description: Cerebellar and brainstem involvement contributes to ataxia.
causal_link_type: DIRECT
evidence:
- reference: PMID:38731973
reference_title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.'
supports: SUPPORT
evidence_source: OTHER
snippet: Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.
explanation: Wilson disease clinical highlights list ataxia among features explained by copper injury to organs including the brain.
- target: Dysphagia
description: Bulbar motor dysfunction contributes to dysphagia.
causal_link_type: DIRECT
evidence:
- reference: PMID:28433096
reference_title: 'Wilson disease: neurologic features.'
supports: SUPPORT
evidence_source: OTHER
snippet: Wilson disease (WD) is a neurodegenerative disorder, which presents as a spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia
explanation: Supports dysphagia as part of the neurologic manifestation spectrum of Wilson disease neurodegeneration.
- target: Drooling
description: Bulbar dysfunction and impaired swallowing contribute to drooling.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Bulbar dysfunction and impaired swallowing.
evidence:
- reference: PMID:3595645
reference_title: "Presenting symptoms and natural history of Wilson disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: the most frequent were in order of frequency jaundice, dysarthria, clumsiness, tremor, drooling, gait disturbance, malaise and arthralgia
explanation: Large case-series data list drooling among frequent Wilson disease manifestations, consistent with neurologic bulbar dysfunction.
- target: Anxiety
description: Copper-mediated brain injury can contribute to neuropsychiatric symptoms including anxiety.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Neuropsychiatric circuit dysfunction.
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Personality changes, particularly irritability and aggression, were most commonly described (45.9%), followed by depression (27%). Cognitive changes, anxiety, psychosis, and catatonia, while less frequent, also occurred.
explanation: Supports anxiety within the psychiatric manifestation spectrum of Wilson disease neurologic involvement.
- target: Depression
description: Neuropsychiatric brain involvement contributes to depressive symptoms.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Neuropsychiatric circuit dysfunction.
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Personality changes, particularly irritability and aggression, were most commonly described (45.9%), followed by depression (27%). Cognitive changes, anxiety, psychosis, and catatonia, while less frequent, also occurred.
explanation: Supports depression within the psychiatric manifestation spectrum of Wilson disease neurologic involvement.
- target: Psychosis
description: Severe neuropsychiatric involvement can manifest as psychosis.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Neuropsychiatric circuit dysfunction.
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Personality changes, particularly irritability and aggression, were most commonly described (45.9%), followed by depression (27%). Cognitive changes, anxiety, psychosis, and catatonia, while less frequent, also occurred.
explanation: Supports psychosis within the psychiatric manifestation spectrum of Wilson disease neurologic involvement.
- target: Personality Changes
description: Fronto-striatal and related network dysfunction can manifest as personality change.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Fronto-striatal and related neuropsychiatric circuit dysfunction.
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Personality changes, particularly irritability and aggression, were most commonly described (45.9%), followed by depression (27%). Cognitive changes, anxiety, psychosis, and catatonia, while less frequent, also occurred.
explanation: Supports personality changes within the psychiatric manifestation spectrum of Wilson disease neurologic involvement.
- target: Intellectual Disability
description: Copper-related brain injury can cause cognitive dysfunction; the intellectual-disability HPO mapping is retained as a broader cognitive phenotype.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Cognitive dysfunction from copper-related neural injury.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001249 | Intellectual disability | Very frequent (99-80%)
explanation: Orphanet records intellectual disability as a Wilson disease phenotype; the edge models it downstream of copper-related neurologic injury.
- target: Seizure
description: Structural and metabolic brain involvement can lower seizure threshold in a subset of patients.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Copper-related brain lesions and neuroinflammation.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001250 | Seizure | Occasional (29-5%)
explanation: Orphanet records seizure as a Wilson disease phenotype; the edge models it downstream of copper-related neurologic injury.
- target: Gait Disturbance
description: Basal ganglia, cerebellar, and brainstem involvement can disrupt gait.
causal_link_type: DIRECT
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0001288 | Gait disturbance | Very frequent (99-80%)
explanation: Orphanet records gait disturbance as a Wilson disease phenotype; the edge models it downstream of copper-related neurologic injury.
- target: Clumsiness
description: Motor-circuit involvement can present clinically as clumsiness.
causal_link_type: DIRECT
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0002312 | Clumsiness | Very frequent (99-80%)
explanation: Orphanet records clumsiness as a Wilson disease phenotype; the edge models it downstream of copper-related neurologic injury.
- target: Excessive Salivation
description: Bulbar dysfunction and impaired swallowing can produce excessive salivation.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Bulbar motor dysfunction and dysphagia.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0003781 | Excessive salivation | Occasional (29-5%)
explanation: Orphanet records excessive salivation as a Wilson disease phenotype; the edge models it downstream of copper-related neurologic injury.
- target: Proximal Lower Limb Muscle Weakness
description: Neurologic motor involvement and systemic muscle effects can present as proximal lower-limb weakness.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Extrapyramidal motor dysfunction and Wilson disease muscle involvement.
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0008994 | Proximal muscle weakness in lower limbs | Very frequent (99-80%)
explanation: Orphanet records proximal lower limb muscle weakness as a Wilson disease phenotype; the edge models it downstream of copper-related neurologic injury.
- target: Focal T2 Hyperintense Brainstem Lesion
description: Brainstem involvement on MRI reflects focal structural injury within neurologic Wilson disease.
causal_link_type: DIRECT
evidence:
- reference: ORPHA:905
reference_title: Wilson disease (Orphanet structured-database record)
supports: SUPPORT
evidence_source: OTHER
snippet: HP:0012748 | Focal T2 hyperintense brainstem lesion | Occasional (29-5%)
explanation: Orphanet records focal t2 hyperintense brainstem lesion as a Wilson disease phenotype; the edge models it downstream of copper-related neurologic injury.
- target: Aggressive Behavior
description: Neuropsychiatric involvement can manifest with irritability and aggression.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Psychiatric manifestations of copper-related brain involvement.
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Personality changes, particularly irritability and aggression, were most commonly described (45.9%), followed by depression (27%). Cognitive changes, anxiety, psychosis, and catatonia, while less frequent, also occurred.
explanation: Supports aggressive behavior within the psychiatric manifestation spectrum of Wilson disease neurologic involvement.
- name: Cuproptosis
description: >
Copper-dependent cell death has been proposed in Wilson disease, involving
binding of copper to lipoylated enzymes in the tricarboxylic acid (TCA)
cycle and leading to proteotoxic stress and mitochondrial dysfunction. The
strongest Wilson disease-specific evidence currently comes from ATP7B
knockout mouse and copper-treated hepatocyte models rather than human tissue.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: PARTIAL
snippet: "Many interesting disease details were published on the mechanistic steps, such as the generation of reactive oxygen species (ROS) and cuproptosis causing a copper dependent cell death"
explanation: Supports cuproptosis as a proposed mechanistic contributor in Wilson disease, but not yet as a definitively established pathway in patients.
- reference: PMID:41006805
reference_title: "The pathogenesis of liver fibrosis in Wilson's disease: hepatocyte injury and regulation mediated by copper metabolism dysregulation."
supports: PARTIAL
snippet: "Moreover, abnormal lipoylation of the copper-dependent proteins metal-binding domain of ferredoxin 1 and dihydrolipoamide transacetylase causes mitochondrial protein oligomer buildup and tricarboxylic acid cycle dysfunction, reinforcing an \"oxidative damage-inflammation-fibrosis\" vicious cycle."
explanation: A recent mechanistic review links abnormal lipoylation and TCA-cycle dysfunction to Wilson disease liver injury, providing hypothesis-level support for cuproptosis-related biology.
- reference: PMID:35298263
reference_title: "Copper induces cell death by targeting lipoylated TCA cycle proteins."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "copper-dependent, regulated cell death is distinct from known death mechanisms and is dependent on mitochondrial respiration."
explanation: Establishes the distinct mitochondrial cell-death mechanism that underlies the cuproptosis hypothesis.
- reference: PMID:41230834
reference_title: "Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Cuproptosis markers (FDX1, DLST, DLAT, LIAS) were upregulated in both liver tissue"
explanation: Provides direct Wilson disease model-organism evidence for altered cuproptosis markers in ATP7B-deficient liver tissue.
- reference: PMID:41230834
reference_title: "Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Copper exposure decreased cell viability and increased LDH release, exacerbated by Elesclomol and alleviated by Tetrathiomolybdate."
explanation: Provides in vitro support that copper exposure injures hepatocyte-like cells in a cuproptosis-modulated context.
biological_processes:
- preferred_term: cuproptosis
term:
id: GO:0160119
label: cuproptosis
- name: Ferroptosis
description: >
Iron-related cell death pathway involving phospholipid peroxidation.
Secondary hepatic iron overload has been documented in a subset of Wilson
disease patients, raising the possibility of ferroptotic injury alongside
copper-mediated toxicity. This remains an emerging modifier mechanism rather
than a universal explanation for Wilson disease liver injury.
evidence:
- reference: PMID:39733327
reference_title: "Iron and Copper Liver Concentrations in Wilson Disease."
supports: PARTIAL
snippet: "13 (8%) patients aged 13 or older had a hepatic iron index >1.0 which may indicate secondary iron overload."
explanation: Supports that secondary hepatic iron overload can occur in Wilson disease, which provides biologic plausibility for ferroptosis but does not directly prove it.
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: PARTIAL
snippet: "In the liver of patients with Wilson disease, also, increased iron deposits were found that may lead to iron-related ferroptosis responsible for phospholipid peroxidation within membranes of subcellular organelles"
explanation: Supports ferroptosis as an emerging inference from observed hepatic iron deposition rather than a directly proven disease mechanism.
- reference: PMID:41966025
reference_title: "Quercetin alleviates liver injury in Wilson's disease by inhibiting ferroptosis."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Mechanistically, QUE was confirmed to directly bind to ACSL4 and inhibit the ACSL4/LPCAT3/ALOX15 signaling pathway, thereby blocking ferroptosis."
explanation: Cellular and biochemical validation, rather than in vivo animal data alone, supports ACSL4/LPCAT3/ALOX15-linked ferroptosis as an emerging, targetable injury pathway.
- reference: PMID:16940238
reference_title: "Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Decreased ratios of reduced glutathione (GSH) to oxidized glutathione (GSSG) and increased thiobarbituric acid reactive substance (TBARS), a lipid peroxidation product, were found in every affected patient, especially in group II and III patients."
explanation: Human liver tissue shows glutathione depletion and lipid peroxidation, supporting a ferroptosis-permissive biochemical context without proving canonical ferroptosis.
biological_processes:
- preferred_term: ferroptosis
term:
id: GO:0097707
label: ferroptosis
discussions:
- discussion_id: gap_wilson_cuproptosis_human_validation
prompt: >-
Does cuproptosis occur as a copper-driven hepatocyte death program in human
Wilson disease liver, or are the current cuproptosis signals primarily
model-system proxies for broader copper toxicity?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Cuproptosis
- pathophysiology#Ferroptosis
rationale: >-
The disease entry now carries both cuproptosis and ferroptosis as emerging
injury layers. Resolving whether lipoylated-protein aggregation and
cuproptosis-specific rescue are present in human ATP7B-deficient hepatocytes
would clarify which cell-death pathway is causal, which is a modifier, and
which readouts should be prioritized for therapy testing.
proposed_experiments:
- experiment_id: exp_wilson_human_hepatic_organoid_cuproptosis_rescue
name: ATP7B-deficient hepatic organoid cuproptosis rescue assay
description: >-
Compare isogenic ATP7B-deficient and corrected human hepatic organoids
under copper overload, elesclomol amplification, and tetrathiomolybdate
rescue to test whether cuproptosis-specific markers and hepatocyte injury
behave as a coherent, reversible mechanism.
experiment_type:
preferred_term: isogenic rescue perturbation experiment
model_systems:
- name: ATP7B-deficient human hepatic organoid
description: >-
Human hepatic organoid or hepatocyte-like organoid engineered or
selected for ATP7B loss, paired with an isogenic corrected control.
experimental_model_type: ORGANOID
namo_type: namo:Organoid
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
tissue_term:
preferred_term: liver
term:
id: UBERON:0002107
label: liver
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
perturbations:
- name: ATP7B loss
target: gene#ATP7B
gene:
preferred_term: ATP7B
term:
id: hgnc:870
label: ATP7B
effect: Impairs copper export and creates the disease-relevant copper-retention state.
- name: Copper overload
target: pathophysiology#Hepatic Copper Accumulation
chemical_entities:
- preferred_term: copper
biological_processes:
- preferred_term: cuproptosis
term:
id: GO:0160119
label: cuproptosis
- name: Tetrathiomolybdate rescue
target: pathophysiology#Cuproptosis
chemical_entities:
- preferred_term: tetrathiomolybdate
effect: Tests reversibility of copper-driven injury.
readouts:
- name: Cuproptosis marker induction
target: pathophysiology#Cuproptosis
description: >
FDX1, DLST, DLAT, and LIAS expression plus lipoylated-protein abundance
and aggregation.
biological_processes:
- preferred_term: cuproptosis
term:
id: GO:0160119
label: cuproptosis
assays:
- preferred_term: targeted proteomics
- preferred_term: transcriptomic profiling
direction: POSITIVE
- name: Hepatocyte injury and viability
target: pathophysiology#Hepatocyte Injury
description: LDH release, viability, mitochondrial respiration, and stress morphology.
assays:
- preferred_term: cell viability assay
- preferred_term: lactate dehydrogenase release assay
direction: NEGATIVE
interpretation: >-
Copper-induced injury that is increased by elesclomol and attenuated by
tetrathiomolybdate would support a copper-dependent death mechanism.
- name: Ferroptosis discrimination
target: pathophysiology#Ferroptosis
description: >
Lipid peroxidation and ACSL4/LPCAT3/ALOX15 pathway readouts to separate
cuproptosis from iron-linked ferroptosis.
biological_processes:
- preferred_term: ferroptosis
term:
id: GO:0097707
label: ferroptosis
assays:
- preferred_term: lipid peroxidation assay
direction: THRESHOLD_DEPENDENT
controls:
- name: Isogenic ATP7B-corrected organoids
description: Corrected organoids exposed to the same copper and rescue conditions.
- name: Vehicle-treated ATP7B-deficient organoids
description: Disease-model organoids without copper-overload or rescue perturbation.
decision_criterion: >-
Cuproptosis is supported if ATP7B loss plus copper overload induces
lipoylated-protein aggregation, FDX1/DLAT/DLST/LIAS marker changes, and
hepatocyte injury that is attenuated by copper chelation/rescue more
strongly than by ferroptosis-specific controls.
would_support:
- pathophysiology#Cuproptosis
would_refute:
- pathophysiology#Cuproptosis
evidence:
- reference: PMID:41230834
reference_title: "Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Cuproptosis markers (FDX1, DLST, DLAT, LIAS) were upregulated in both liver tissue"
explanation: >-
Model-organism evidence identifies the specific cuproptosis marker set
the proposed human organoid assay would validate.
- reference: PMID:41230834
reference_title: "Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Copper exposure decreased cell viability and increased LDH release, exacerbated by Elesclomol and alleviated by Tetrathiomolybdate."
explanation: >-
The in vitro copper/elesclomol/tetrathiomolybdate pattern motivates a
more disease-relevant human ATP7B-deficient organoid rescue experiment.
evidence:
- reference: PMID:41230834
reference_title: "Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "Cuproptosis markers (FDX1, DLST, DLAT, LIAS) were upregulated in both liver tissue"
explanation: >-
Supports the cuproptosis signal in Wilson disease models while leaving
human tissue and human organoid validation unresolved.
- reference: PMID:41966025
reference_title: "Quercetin alleviates liver injury in Wilson's disease by inhibiting ferroptosis."
supports: PARTIAL
evidence_source: IN_VITRO
snippet: "Mechanistically, QUE was confirmed to directly bind to ACSL4 and inhibit the ACSL4/LPCAT3/ALOX15 signaling pathway, thereby blocking ferroptosis."
explanation: >-
Supports a competing or superimposed ferroptosis mechanism that the
proposed experiment should distinguish from cuproptosis.
- discussion_id: gap_wilson_brain_copper_vs_liver_inflammation
prompt: >-
In neurological Wilson disease, how much of the neuronal injury is driven by
direct brain copper deposition versus liver-derived inflammatory signaling
transmitted through a liver-brain axis, and does this balance shift across
ATP7B genotypes and disease stages?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Neurodegeneration
- pathophysiology#Hepatocyte Injury
rationale: >-
The canonical model attributes neurological Wilson disease to direct
striatal copper deposition, but a genetically precise Atp7b R778L mouse
model developed neurobehavioral deficits, CNS cytokine elevation, and
microglial activation without a measurable rise in brain copper, and
suppressing hepatic inflammation reversed the deficits. Resolving the
relative contribution of brain copper toxicity versus liver-derived
inflammation would clarify whether anti-inflammatory or liver-directed
therapies could prevent or reverse neurological manifestations independent
of brain copper burden.
proposed_experiments:
- experiment_id: exp_wilson_hepatic_inflammation_suppression_brain_copper_stratified
name: Liver-directed anti-inflammatory rescue with brain-copper stratification
description: >-
In Wilson disease animal models, stratify by quantitative brain copper and
test whether liver-targeted anti-inflammatory intervention improves
neurobehavioral outcomes independently of brain copper levels, to separate
direct brain copper toxicity from liver-derived inflammatory injury.
experiment_type:
preferred_term: in vivo intervention experiment
model_systems:
- name: Atp7b R778L Wilson disease mouse
description: >-
Genetically precise Atp7b R778L knock-in mouse recapitulating East Asian
Wilson disease genotype with hepatic and neurological phenotypes.
organism:
preferred_term: house mouse
term:
id: NCBITaxon:10090
label: Mus musculus
tissue_term:
preferred_term: brain
term:
id: UBERON:0000955
label: brain
cell_types:
- preferred_term: microglial cell
term:
id: CL:0000129
label: microglial cell
perturbations:
- name: Hepatic inflammation suppression
target: pathophysiology#Hepatocyte Injury
effect: Suppresses liver-derived inflammatory signaling to the CNS.
readouts:
- name: Neurobehavioral function
target: pathophysiology#Neurodegeneration
description: Motor coordination and cognitive performance.
direction: POSITIVE
- name: Brain copper concentration
target: pathophysiology#Systemic Copper Distribution
description: Quantitative brain tissue copper used for stratification.
direction: THRESHOLD_DEPENDENT
- name: CNS neuroinflammation
target: pathophysiology#Neurodegeneration
description: CNS inflammatory cytokine levels and microglial activation state.
biological_processes:
- preferred_term: neuroinflammatory response
term:
id: GO:0150076
label: neuroinflammatory response
direction: NEGATIVE
controls:
- name: Vehicle-treated Atp7b R778L mice
description: Disease-model mice without anti-inflammatory intervention.
- name: Wild-type littermates
description: Genotype controls with normal copper handling.
decision_criterion: >-
A liver-derived inflammatory mechanism is supported if hepatic
inflammation suppression improves neurobehavioral outcomes and reduces CNS
neuroinflammation without lowering brain copper; a direct brain-copper
mechanism is favored if outcomes track brain copper rather than
inflammation.
would_support:
- pathophysiology#Neurodegeneration
evidence:
- reference: PMID:39334421
reference_title: "Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "inhibition of hepatic inflammation with PJ34 or siNfkb markedly alleviated the deficiencies in cognitive performance and improved locomotor activity in R778L mice"
explanation: >-
Establishes the intervention and readouts the stratified experiment
would extend across brain-copper strata.
evidence:
- reference: PMID:39334421
reference_title: "Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "the Cu2+ levels in the brain tissue of R778L mice did not differ significantly from those of wild-type mice"
explanation: >-
Supports the existence of the gap by showing neurological deficits without
a measurable brain copper increase, leaving the human contribution of each
mechanism unresolved.
phenotypes:
- name: Hepatomegaly
category: Hepatic
frequency: OCCASIONAL
notes: >-
Base frequency follows pediatric cohort evidence; Orphanet's curated HPO
annotation gives a higher very-frequent band.
evidence:
- reference: PMID:22473403
reference_title: "Wilson's disease: an analysis of 28 Brazilian children."
supports: SUPPORT
snippet: "three had hepatomegaly associated with neurological disorders"
explanation: Pediatric cohort data directly support hepatomegaly as an occasional presenting phenotype in Wilson disease.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives hepatomegaly a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies hepatomegaly as very frequent in Wilson disease.
phenotype_term:
preferred_term: Hepatomegaly
term:
id: HP:0002240
label: Hepatomegaly
- name: Jaundice
category: Hepatic
frequency: VERY_FREQUENT
evidence:
- reference: PMID:3595645
reference_title: "Presenting symptoms and natural history of Wilson disease."
supports: SUPPORT
snippet: "the most frequent were in order of frequency jaundice, dysarthria, clumsiness, tremor, drooling, gait disturbance, malaise and arthralgia"
explanation: Large case-series data identify jaundice among the common presenting symptoms of Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000952 | Jaundice | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies jaundice as very frequent in Wilson disease.
phenotype_term:
preferred_term: Jaundice
term:
id: HP:0000952
label: Jaundice
- name: Bruising Susceptibility
category: Hepatic
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000978 | Bruising susceptibility | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies bruising susceptibility as very frequent in Wilson disease.
phenotype_term:
preferred_term: Bruising susceptibility
term:
id: HP:0000978
label: Bruising susceptibility
- name: Pruritus
category: Hepatic
notes: >-
Base frequency is intentionally omitted because pruritus is not a core
high-frequency Wilson disease manifestation in clinical guidance; the
Orphanet curated annotation is retained as source-specific context.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives pruritus a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000989 | Pruritus | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies pruritus as very frequent in Wilson disease.
phenotype_term:
preferred_term: Pruritus
term:
id: HP:0000989
label: Pruritus
- name: Hepatic Steatosis
category: Hepatic
frequency: VERY_FREQUENT
evidence:
- reference: PMID:28433112
reference_title: "Wilson disease - liver pathology."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis."
explanation: Liver biopsy review data support hepatic steatosis as a common histopathological phenotype in Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001397 | Hepatic steatosis | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies hepatic steatosis as very frequent in Wilson disease.
phenotype_term:
preferred_term: Hepatic steatosis
term:
id: HP:0001397
label: Hepatic steatosis
- name: Cirrhosis
category: Hepatic
frequency: FREQUENT
notes: >-
Can be a presenting feature or develop over time; base frequency follows
cohort evidence, while Orphanet's curated HPO annotation uses a higher
very-frequent band.
evidence:
- reference: PMID:35197085
reference_title: "Wilson disease in Northern Portugal: a long-term follow-up study."
supports: SUPPORT
snippet: "Four patients (17%) presented with acute liver failure and fifteen (63%) individuals had cirrhosis at diagnosis."
explanation: Cohort data support cirrhosis as a common presenting hepatic phenotype in Wilson disease.
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: PARTIAL
snippet: "Liver transplantation is an option viewed as ultima ratio in end-stage liver disease with untreatable complications or acute liver failure."
explanation: End-stage liver disease including cirrhosis is a major complication requiring transplantation.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives cirrhosis a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001394 | Cirrhosis | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies cirrhosis as very frequent in Wilson disease.
phenotype_term:
preferred_term: Cirrhosis
term:
id: HP:0001394
label: Cirrhosis
- name: Acute Hepatic Failure
category: Hepatic
frequency: OCCASIONAL
notes: May be a presenting event that requires urgent transplant evaluation
evidence:
- reference: PMID:35197085
reference_title: "Wilson disease in Northern Portugal: a long-term follow-up study."
supports: SUPPORT
snippet: "Four patients (17%) presented with acute liver failure and fifteen (63%) individuals had cirrhosis at diagnosis."
explanation: Supports acute hepatic failure as a recognized presenting hepatic manifestation in Wilson disease.
- reference: PMID:32520831
reference_title: "Pediatric Wilson Disease Presenting as Acute Liver Failure: An Individual Patient Data Meta-analysis."
supports: SUPPORT
snippet: "Of the total 256 subjects, 87% underwent LT, 11% achieved spontaneous recovery and 2% died before LT."
explanation: Supports that Wilson disease-associated acute liver failure is a severe presentation that frequently requires transplantation.
phenotype_term:
preferred_term: Acute hepatic failure
term:
id: HP:0006554
label: Acute hepatic failure
- name: Ascites
category: Hepatic
frequency: OCCASIONAL
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001541 | Ascites | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies ascites as occasional in Wilson disease.
phenotype_term:
preferred_term: Ascites
term:
id: HP:0001541
label: Ascites
- name: Hepatitis
category: Hepatic
frequency: VERY_FREQUENT
notes: May present as chronic hepatitis or acute hepatitis
evidence:
- reference: PMID:28433112
reference_title: "Wilson disease - liver pathology."
supports: SUPPORT
snippet: "Most liver biopsy specimens show moderate to severe steatosis, variable degree of portal and/or lobular inflammation, and fibrosis eventually progressing to cirrhosis."
explanation: Liver biopsy findings of portal and lobular inflammation are consistent with hepatitis as a very frequent hepatic presentation.
- reference: PMID:28433112
reference_title: "Wilson disease - liver pathology."
supports: SUPPORT
snippet: "Wilson disease may be microscopically misinterpreted as many other liver diseases, including viral or autoimmune hepatitis, alcoholic/nonalcoholic steatohepatitis, toxic liver injury, cryptogenic cirrhosis"
explanation: Wilson disease liver pathology frequently mimics hepatitis patterns, confirming hepatitis-like presentation.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0012115 | Hepatitis | Very frequent (99-80%)"
explanation: Orphanet's HPO table independently classifies hepatitis as very frequent in Wilson disease.
phenotype_term:
preferred_term: Hepatitis
term:
id: HP:0012115
label: Hepatitis
- name: Acute Hepatitis
category: Hepatic
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0200119 | Acute hepatitis | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies acute hepatitis as very frequent in Wilson disease.
phenotype_term:
preferred_term: Acute hepatitis
term:
id: HP:0200119
label: Acute hepatitis
- name: Elevated Circulating Hepatic Transaminase Concentration
category: Biochemical
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002910 | Elevated circulating hepatic transaminase concentration | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies elevated circulating hepatic transaminase concentration as very frequent in Wilson disease.
phenotype_term:
preferred_term: Elevated circulating hepatic transaminase concentration
term:
id: HP:0002910
label: Elevated circulating hepatic transaminase concentration
- name: Splenomegaly
category: Hepatic
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001744 | Splenomegaly | Very frequent (99-80%)"
explanation: Orphanet's HPO table lists splenomegaly as very frequent in Wilson disease.
phenotype_term:
preferred_term: Splenomegaly
term:
id: HP:0001744
label: Splenomegaly
- name: Kayser-Fleischer Rings
category: Ocular
frequency: FREQUENT
diagnostic: true
notes: >-
Copper deposits in Descemet membrane, pathognomonic; base frequency follows
cohort detection data, while Orphanet's curated HPO annotation uses a
higher very-frequent band.
evidence:
- reference: PMID:16709660
reference_title: "Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study."
supports: SUPPORT
snippet: "Diagnostic criteria for non-caeruloplasmin-bound serum copper, serum caeruloplasmin, 24-h urinary copper excretion, liver copper content, presence of Kayser-Fleischer rings and histological signs of chronic liver damage were reached in 86.6%, 88.2%, 87.1%, 92.7%, 66.3% and 73% of patients, respectively."
explanation: Large-cohort data confirm frequent Kayser-Fleischer ring detection in diagnosed Wilson disease.
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings"
explanation: Confirms Kayser-Fleischer rings as a key clinical feature of Wilson's disease due to copper deposition in the eyes.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives Kayser-Fleischer ring a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0200032 | Kayser-Fleischer ring | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies Kayser-Fleischer ring as very frequent in Wilson disease.
phenotype_term:
preferred_term: Kayser-Fleischer ring
term:
id: HP:0200032
label: Kayser-Fleischer ring
- name: Sunflower Cataract
category: Ocular
frequency: VERY_RARE
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:6000642 | Sunflower cataract | Very rare (<4-1%)"
explanation: Orphanet's HPO table records sunflower cataract as a very rare ocular manifestation of Wilson disease.
phenotype_term:
preferred_term: Sunflower cataract
term:
id: HP:6000642
label: Sunflower cataract
- name: Abnormality Of The Menstrual Cycle
category: Reproductive
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000140 | Abnormality of the menstrual cycle | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies abnormality of the menstrual cycle as very frequent in Wilson disease.
phenotype_term:
preferred_term: Abnormality of the menstrual cycle
term:
id: HP:0000140
label: Abnormality of the menstrual cycle
- name: Intellectual Disability
category: Neurological
notes: >-
Base frequency is intentionally omitted because Wilson disease cognitive
dysfunction is not equivalent to formal intellectual disability across most
patients; the Orphanet curated annotation is retained as source-specific
context.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives intellectual disability a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001249 | Intellectual disability | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies intellectual disability as very frequent in Wilson disease.
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
- name: Seizure
category: Neurological
frequency: OCCASIONAL
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies seizure as occasional in Wilson disease.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
- name: Gait Disturbance
category: Neurological
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001288 | Gait disturbance | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies gait disturbance as very frequent in Wilson disease.
phenotype_term:
preferred_term: Gait disturbance
term:
id: HP:0001288
label: Gait disturbance
- name: Clumsiness
category: Neurological
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002312 | Clumsiness | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies clumsiness as very frequent in Wilson disease.
phenotype_term:
preferred_term: Clumsiness
term:
id: HP:0002312
label: Clumsiness
- name: Tremor
category: Neurological
frequency: FREQUENT
notes: Often wing-beating tremor
evidence:
- reference: PMID:33474589
reference_title: "Neurological features and outcomes of Wilson's disease: a single-center experience."
supports: SUPPORT
snippet: "most common neurological manifestation was dystonia, followed by tremor and parkinsonism."
explanation: Cohort data directly identify tremor as a common neurologic manifestation.
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Supports tremor as part of the core neurologic phenotype spectrum.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001337 | Tremor | Frequent (79-30%)"
explanation: Orphanet's HPO table classifies tremor as frequent in Wilson disease, matching the curated frequency band.
phenotype_term:
preferred_term: Tremor
term:
id: HP:0001337
label: Tremor
- name: Dystonia
category: Neurological
frequency: FREQUENT
evidence:
- reference: PMID:33474589
reference_title: "Neurological features and outcomes of Wilson's disease: a single-center experience."
supports: SUPPORT
snippet: "most common neurological manifestation was dystonia, followed by tremor and parkinsonism."
explanation: Cohort data support dystonia as the most common neurologic manifestation in this series.
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Supports dystonia as a core feature of neurologic Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001332 | Dystonia | Frequent (79-30%)"
explanation: Orphanet's HPO table classifies dystonia as frequent in Wilson disease, matching the curated frequency band.
phenotype_term:
preferred_term: Dystonia
term:
id: HP:0001332
label: Dystonia
- name: Parkinsonism
category: Neurological
frequency: OCCASIONAL
notes: May include bradykinesia, rigidity, and tremor
evidence:
- reference: PMID:33474589
reference_title: "Neurological features and outcomes of Wilson's disease: a single-center experience."
supports: SUPPORT
snippet: "most common neurological manifestation was dystonia, followed by tremor and parkinsonism."
explanation: Cohort data directly report parkinsonism among predominant neurologic presentations.
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Supports parkinsonian-spectrum motor features in neurologic Wilson disease.
phenotype_term:
preferred_term: Parkinsonism
term:
id: HP:0001300
label: Parkinsonism
- name: Bradykinesia
category: Neurological
frequency: OCCASIONAL
evidence:
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Supports bradykinesia as part of the neurologic movement phenotype spectrum.
phenotype_term:
preferred_term: Bradykinesia
term:
id: HP:0002067
label: Bradykinesia
- name: Rigidity
category: Neurological
frequency: OCCASIONAL
evidence:
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Supports rigidity as part of the neurologic movement phenotype spectrum.
phenotype_term:
preferred_term: Rigidity
term:
id: HP:0002063
label: Rigidity
- name: Chorea
category: Neurological
frequency: OCCASIONAL
evidence:
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Supports chorea as part of the neurologic movement phenotype spectrum.
phenotype_term:
preferred_term: Chorea
term:
id: HP:0002072
label: Chorea
- name: Dysarthria
category: Neurological
frequency: FREQUENT
notes: >-
Base frequency follows the broader clinical evidence already cited; Orphanet's
curated HPO annotation gives a higher very-frequent band.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia"
explanation: Dysarthria is explicitly listed as a neurological manifestation of Wilson disease.
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Confirms dysarthria among core neurologic Wilson disease features.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives dysarthria a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001260 | Dysarthria | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies dysarthria as very frequent in Wilson disease.
phenotype_term:
preferred_term: Dysarthria
term:
id: HP:0001260
label: Dysarthria
- name: Ataxia
category: Neurological
frequency: FREQUENT
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia"
explanation: Ataxia is explicitly listed as a neurological manifestation of Wilson disease.
phenotype_term:
preferred_term: Ataxia
term:
id: HP:0001251
label: Ataxia
- name: Dysphagia
category: Neurological
frequency: FREQUENT
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia"
explanation: Dysphagia is explicitly listed as a neurological manifestation of Wilson disease.
- reference: PMID:28433096
reference_title: "Wilson disease: neurologic features."
supports: SUPPORT
snippet: "spectrum of neurologic manifestations that includes tremor, bradykinesia, rigidity, dystonia, chorea, dysarthria, and dysphagia"
explanation: Confirms dysphagia among the core neurologic manifestations.
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
- name: Excessive Salivation
category: Neurological
frequency: OCCASIONAL
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0003781 | Excessive salivation | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies excessive salivation as occasional in Wilson disease.
phenotype_term:
preferred_term: Excessive salivation
term:
id: HP:0003781
label: Excessive salivation
- name: Proximal Lower Limb Muscle Weakness
category: Neurological
notes: >-
Base frequency is intentionally omitted because proximal lower-limb
weakness at a very-frequent rate is not corroborated in the cited clinical
literature; the Orphanet curated annotation is retained as source-specific
context.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives proximal lower-limb muscle weakness a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0008994 | Proximal muscle weakness in lower limbs | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies proximal muscle weakness in lower limbs as very frequent in Wilson disease.
phenotype_term:
preferred_term: Proximal lower limb muscle weakness
term:
id: HP:0008994
label: Proximal lower limb muscle weakness
- name: Focal T2 Hyperintense Brainstem Lesion
category: Neurological
frequency: OCCASIONAL
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0012748 | Focal T2 hyperintense brainstem lesion | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies focal T2 hyperintense brainstem lesion as occasional in Wilson disease.
phenotype_term:
preferred_term: Focal T2 hyperintense brainstem lesion
term:
id: HP:0012748
label: Focal T2 hyperintense brainstem lesion
- name: Drooling
category: Neurological
evidence:
- reference: PMID:3595645
reference_title: "Presenting symptoms and natural history of Wilson disease."
supports: SUPPORT
snippet: "the most frequent were in order of frequency jaundice, dysarthria, clumsiness, tremor, drooling, gait disturbance, malaise and arthralgia"
explanation: Large case-series data identify drooling as one of the more common presenting symptoms of Wilson disease.
phenotype_term:
preferred_term: Drooling
term:
id: HP:0002307
label: Drooling
- name: Vomiting
category: Gastrointestinal
frequency: OCCASIONAL
evidence:
- reference: PMID:29914392
reference_title: "Three novel mutations in the ATP7B gene of unrelated Vietnamese patients with Wilson disease."
supports: SUPPORT
snippet: "These patients had clinical features such as numbness of hands and feet, vomiting, insomnia, palsy, liver failure and Kayser-Fleischer (K-F) rings"
explanation: HPOA-linked case-series evidence supports vomiting as a gastrointestinal manifestation reported in Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002013 | Vomiting | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies vomiting as occasional in Wilson disease.
phenotype_term:
preferred_term: Vomiting
term:
id: HP:0002013
label: Vomiting
- name: Abdominal Pain
category: Gastrointestinal
frequency: OCCASIONAL
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002027 | Abdominal pain | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies abdominal pain as occasional in Wilson disease.
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
- name: Failure To Thrive
category: Constitutional
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001508 | Failure to thrive | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies failure to thrive as very frequent in Wilson disease.
phenotype_term:
preferred_term: Failure to thrive
term:
id: HP:0001508
label: Failure to thrive
- name: Weight Loss
category: Constitutional
frequency: VERY_FREQUENT
notes: >-
Orphanet also lists increased body weight as very frequent, which conflicts
with this weight-loss annotation; the weight-loss phenotype is retained and
the contradictory increased-body-weight row is not modeled as a base Wilson
disease phenotype.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001824 | Weight loss | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies weight loss as very frequent in Wilson disease.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- name: Anxiety
category: Psychiatric
frequency: OCCASIONAL
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
snippet: "Cognitive changes, anxiety, psychosis, and catatonia, while less frequent, also occurred."
explanation: Supports anxiety as a recognized psychiatric manifestation of Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000739 | Anxiety | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies anxiety as occasional in Wilson disease.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
- name: Aggressive Behavior
category: Psychiatric
frequency: FREQUENT
notes: >-
Base frequency follows the symptomatic psychiatric cohort estimate for
personality changes including irritability and aggression; Orphanet's
curated HPO annotation uses a higher very-frequent band.
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
snippet: |-
Personality changes, particularly irritability and aggression, were most
commonly described (45.9%), followed by depression (27%). Cognitive changes,
explanation: Cohort data support aggressive behavior as part of the frequent personality-change presentation in symptomatic Wilson disease.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives aggressive behavior a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000718 | Aggressive behavior | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies aggressive behavior as very frequent in Wilson disease.
phenotype_term:
preferred_term: Aggressive behavior
term:
id: HP:0000718
label: Aggressive behavior
- name: Depression
category: Psychiatric
frequency: OCCASIONAL
notes: >-
One of the most common psychiatric manifestations of Wilson disease; the
base frequency follows the 27% symptomatic-cohort estimate, while Orphanet's
curated HPO annotation uses a higher frequency band.
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
snippet: "followed by depression (27%)."
explanation: Cohort data directly support depression as a common psychiatric manifestation in symptomatic Wilson disease.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives depression a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000716 | Depression | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies depression as very frequent in Wilson disease.
phenotype_term:
preferred_term: Depression
term:
id: HP:0000716
label: Depression
- name: Psychosis
category: Psychiatric
frequency: OCCASIONAL
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
snippet: "Cognitive changes, anxiety, psychosis, and catatonia, while less frequent, also occurred."
explanation: Supports psychosis as a recognized, less frequent psychiatric presentation of Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000709 | Psychosis | Occasional (29-5%)"
explanation: Orphanet's HPO table classifies psychosis as occasional in Wilson disease, matching the curated frequency band.
phenotype_term:
preferred_term: Psychosis
term:
id: HP:0000709
label: Psychosis
- name: Personality Changes
category: Psychiatric
frequency: FREQUENT
notes: Personality changes may be an early psychiatric manifestation
evidence:
- reference: PMID:1821256
reference_title: "The psychiatric presentations of Wilson's disease."
supports: SUPPORT
snippet: "Personality changes, particularly irritability and aggression, were most commonly described (45.9%), followed by depression (27%)."
explanation: Directly supports personality change as a common psychiatric presentation in symptomatic Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000751 | Personality changes | Frequent (79-30%)"
explanation: Orphanet's HPO table classifies personality changes as frequent in Wilson disease, matching the curated frequency band.
phenotype_term:
preferred_term: Personality changes
term:
id: HP:0000751
label: Personality changes
- name: Bipolar Affective Disorder
category: Psychiatric
notes: >-
GeneReviews lists bipolar disorder / bipolar spectrum disorder among the
psychiatric presentations of Wilson disease. Frequency is intentionally
omitted because the expert review describes it as one of several possible
psychiatric disturbances without a quantitative band.
evidence:
- reference: PMID:20301685
reference_title: "Wilson Disease (GeneReviews)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Psychiatric disturbances can include depression, bipolar disorder / bipolar spectrum disorder, neurotic behaviors, personality changes, or psychosis"
explanation: GeneReviews explicitly lists bipolar disorder / bipolar spectrum disorder among Wilson disease psychiatric presentations.
phenotype_term:
preferred_term: Bipolar affective disorder
term:
id: HP:0007302
label: Bipolar affective disorder
- name: Hypomimic Face
category: Neurological
notes: >-
Mask-like facies (hypomimia) is a recognized component of the dystonic /
parkinsonian neurologic phenotype of Wilson disease per GeneReviews.
evidence:
- reference: PMID:20301685
reference_title: "Wilson Disease (GeneReviews)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "dystonia (mask-like facies, rigidity, gait disturbance, pseudobulbar involvement), dysautonomia, seizures, sleep disorders, or insomnia"
explanation: GeneReviews lists mask-like facies among the dystonic neurologic features of Wilson disease.
phenotype_term:
preferred_term: Mask-like facies
term:
id: HP:0000338
label: Hypomimic face
- name: Sleep Disturbance
category: Neurological
notes: >-
Sleep disorders and insomnia are recognized neurologic manifestations of
Wilson disease per GeneReviews. Frequency is omitted as the source provides
no quantitative band.
evidence:
- reference: PMID:20301685
reference_title: "Wilson Disease (GeneReviews)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "dystonia (mask-like facies, rigidity, gait disturbance, pseudobulbar involvement), dysautonomia, seizures, sleep disorders, or insomnia"
explanation: GeneReviews lists sleep disorders and insomnia among the neurologic manifestations of Wilson disease.
phenotype_term:
preferred_term: Sleep disturbance
term:
id: HP:0002360
label: Sleep disturbance
- name: Autonomic Dysfunction
category: Neurological
notes: >-
Dysautonomia is listed by GeneReviews among the neurologic presentations of
Wilson disease; mapped to the current non-obsolete HPO autonomic-physiology
term.
evidence:
- reference: PMID:20301685
reference_title: "Wilson Disease (GeneReviews)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "dystonia (mask-like facies, rigidity, gait disturbance, pseudobulbar involvement), dysautonomia, seizures, sleep disorders, or insomnia"
explanation: GeneReviews lists dysautonomia among the neurologic manifestations of Wilson disease.
phenotype_term:
preferred_term: Dysautonomia
term:
id: HP:0012332
label: Abnormal autonomic nervous system physiology
- name: Cardiomyopathy
category: Cardiac
frequency: OCCASIONAL
evidence:
- reference: PMID:27176875
reference_title: "Strain and strain rate echocardiography in children with Wilson's disease."
supports: SUPPORT
snippet: "Cardiac arrhythmias, cardiomyopathy and sudden cardiac death are rare complications but may be seen in children with Wilson's disease due to copper accumulation in the heart tissue."
explanation: Supports cardiomyopathy as a recognized but uncommon cardiac complication of Wilson disease.
phenotype_term:
preferred_term: Cardiomyopathy
term:
id: HP:0001638
label: Cardiomyopathy
- name: Heart Failure
category: Cardiac
evidence:
- reference: PMID:28947309
reference_title: "Wilson's Disease and Cardiac Myopathy."
supports: SUPPORT
snippet: "patients with Wilson's disease had a 55% higher risk of incident HF (HR 1.55, 95% CI 1.41 to 1.71, p <0.0001)"
explanation: Population-level claims data support heart failure as an important cardiac complication of Wilson disease.
phenotype_term:
preferred_term: Congestive heart failure
term:
id: HP:0001635
label: Congestive heart failure
- name: Cardiac Arrhythmia
category: Cardiac
frequency: OCCASIONAL
evidence:
- reference: PMID:28947309
reference_title: "Wilson's Disease and Cardiac Myopathy."
supports: SUPPORT
snippet: "Patients with Wilson's disease exhibited a 29% higher risk of AF after adjusting for age, gender, race, income, hypertension, diabetes, renal disease, hyperlipidemia, obesity, coronary disease, and obstructive sleep apnea (HR 1.29, 95% CI 1.15 to 1.45, p <0.0001)."
explanation: Supports arrhythmia risk as a clinically relevant cardiac manifestation in Wilson disease.
phenotype_term:
preferred_term: Arrhythmia
term:
id: HP:0011675
label: Arrhythmia
- name: Renal Tubular Dysfunction
category: Renal
frequency: OCCASIONAL
notes: Renal tubular acidosis is one documented form of renal tubular involvement
evidence:
- reference: PMID:31317233
reference_title: "Renal Tubular Function, Bone Health and Body Composition in Wilson's Disease: A Cross-Sectional Study from India."
supports: SUPPORT
snippet: "Fifty-six percent (14/25) of patients with WD had renal tubular acidosis (RTA)."
explanation: Supports renal tubular dysfunction in Wilson disease through direct evidence of a high prevalence of renal tubular acidosis.
phenotype_term:
preferred_term: Renal tubular dysfunction
term:
id: HP:0000124
label: Renal tubular dysfunction
- name: Thrombocytopenia
category: Hematologic
frequency: VERY_FREQUENT
notes: >-
Frequency reflects the Orphanet curated HPO annotation; thrombocytopenia in
Wilson disease is often stage-dependent, including portal hypertension or
hypersplenism contexts.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001873 | Thrombocytopenia | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies thrombocytopenia as very frequent in Wilson disease.
phenotype_term:
preferred_term: Thrombocytopenia
term:
id: HP:0001873
label: Thrombocytopenia
- name: Anemia
category: Hematologic
frequency: VERY_FREQUENT
notes: >-
Frequency reflects the Orphanet curated HPO annotation; anemia in Wilson
disease can be stage- or presentation-dependent, including hemolytic and
advanced liver disease contexts.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001903 | Anemia | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies anemia as very frequent in Wilson disease.
phenotype_term:
preferred_term: Anemia
term:
id: HP:0001903
label: Anemia
- name: Hemolytic Anemia
category: Hematologic
frequency: OCCASIONAL
notes: May accompany acute hepatic decompensation with marked copper release
evidence:
- reference: PMID:24577547
reference_title: "Acute hemolytic anemia as an initial presentation of Wilson disease in children."
supports: SUPPORT
snippet: "Hemolytic anemia in WD occurs in up to 17% of patients at some point during their illness."
explanation: Supports hemolytic anemia as a recognized hematologic manifestation of Wilson disease.
- reference: PMID:7234865
reference_title: "Hemolytic anemia in Wilson disease: clinical findings and biochemical mechanisms."
supports: SUPPORT
snippet: "Two patients with Wilson disease who presented with severe hemolytic anemia are described."
explanation: Provides direct case-based evidence of severe hemolytic anemia in Wilson disease.
phenotype_term:
preferred_term: Hemolytic anemia
term:
id: HP:0001878
label: Hemolytic anemia
- name: Bone Pain
category: Skeletal
frequency: VERY_FREQUENT
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002653 | Bone pain | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies bone pain as very frequent in Wilson disease.
phenotype_term:
preferred_term: Bone pain
term:
id: HP:0002653
label: Bone pain
- name: Arthritis
category: Skeletal
notes: >-
Base frequency is intentionally omitted because a very-frequent inflammatory
arthritis rate is not independently corroborated in the cited clinical
literature; the Orphanet curated annotation is retained as source-specific
context.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives arthritis a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001369 | Arthritis | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies arthritis as very frequent in Wilson disease.
phenotype_term:
preferred_term: Arthritis
term:
id: HP:0001369
label: Arthritis
- name: Joint Swelling
category: Skeletal
notes: >-
Base frequency is intentionally omitted because a very-frequent joint
swelling rate is not independently corroborated in the cited clinical
literature; the Orphanet curated annotation is retained as source-specific
context.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives joint swelling a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001386 | Joint swelling | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies joint swelling as very frequent in Wilson disease.
phenotype_term:
preferred_term: Joint swelling
term:
id: HP:0001386
label: Joint swelling
- name: Pathologic Fracture
category: Skeletal
notes: >-
Base frequency is intentionally omitted because pathologic fracture should
be a subset of low bone density complications rather than a very-frequent
unselected Wilson disease feature; the Orphanet curated annotation is
retained as source-specific context.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives pathologic fracture a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002756 | Pathologic fracture | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies pathologic fracture as very frequent in Wilson disease.
phenotype_term:
preferred_term: Pathologic fracture
term:
id: HP:0002756
label: Pathologic fracture
- name: Osteoporosis
category: Skeletal
frequency: FREQUENT
evidence:
- reference: PMID:29110062
reference_title: "Osteoporosis and bone mineral density in patients with Wilson's disease: a systematic review and meta-analysis."
supports: SUPPORT
snippet: "The pooled prevalencerates of osteopenia and osteoporosis in WD patients were 36.5%"
explanation: Meta-analysis supports frequent low bone density and osteoporosis in Wilson disease populations.
- reference: PMID:31317233
reference_title: "Renal Tubular Function, Bone Health and Body Composition in Wilson's Disease: A Cross-Sectional Study from India."
supports: SUPPORT
snippet: "Patients with WD had significantly lower BMD as compared to control subjects (p < 0.05)."
explanation: Supports reduced bone mineral density as a real skeletal manifestation in Wilson disease cohorts.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000939 | Osteoporosis | Frequent (79-30%)"
explanation: Orphanet's HPO table classifies osteoporosis as frequent in Wilson disease, matching the meta-analysis-supported frequency band.
phenotype_term:
preferred_term: Osteoporosis
term:
id: HP:0000939
label: Osteoporosis
- name: Osteopenia
category: Skeletal
evidence:
- reference: PMID:29110062
reference_title: "Osteoporosis and bone mineral density in patients with Wilson's disease: a systematic review and meta-analysis."
supports: SUPPORT
snippet: "The pooled prevalencerates of osteopenia and osteoporosis in WD patients were 36.5%"
explanation: Meta-analysis supports osteopenia as a common bone phenotype in Wilson disease.
- reference: PMID:31317233
reference_title: "Renal Tubular Function, Bone Health and Body Composition in Wilson's Disease: A Cross-Sectional Study from India."
supports: SUPPORT
snippet: "Patients with WD had significantly lower BMD as compared to control subjects (p < 0.05)."
explanation: Independent cohort data support low bone mass in Wilson disease.
phenotype_term:
preferred_term: Osteopenia
term:
id: HP:0000938
label: Osteopenia
- name: Arthralgia
category: Skeletal
notes: >-
Base frequency is not assigned from the presenting-symptom list alone;
Orphanet's curated HPO annotation gives a very-frequent frequency band.
evidence:
- reference: PMID:3595645
reference_title: "Presenting symptoms and natural history of Wilson disease."
supports: SUPPORT
snippet: "the most frequent were in order of frequency jaundice, dysarthria, clumsiness, tremor, drooling, gait disturbance, malaise and arthralgia"
explanation: Large case-series data identify arthralgia among the more common presenting symptoms of Wilson disease.
phenotype_contexts:
- population: Orphanet curated HPO annotation
frequency: VERY_FREQUENT
notes: Orphanet's structured HPO table gives arthralgia a very-frequent frequency band.
evidence:
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002829 | Arthralgia | Very frequent (99-80%)"
explanation: Orphanet's HPO table classifies arthralgia as very frequent in Wilson disease.
phenotype_term:
preferred_term: Arthralgia
term:
id: HP:0002829
label: Arthralgia
biochemical:
- name: Ceruloplasmin
presence: Decreased
context: Low in over 90 percent of patients (less than 20 mg/dL)
readouts:
- target: Impaired Ceruloplasmin Loading
relationship: READOUT_OF
direction: NEGATIVE
endpoint_context: DIAGNOSTIC
interpretation: Low circulating ceruloplasmin reports failed ATP7B-dependent copper incorporation into apoceruloplasmin.
evidence:
- reference: PMID:15205951
reference_title: Wilson disease.
supports: SUPPORT
evidence_source: OTHER
snippet: The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content.
explanation: Supports low serum ceruloplasmin as a diagnostic biochemical readout of Wilson disease copper-handling failure.
evidence:
- reference: PMID:15205951
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content."
explanation: Directly supports low serum ceruloplasmin as a diagnostic biochemical feature.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0010837 | Decreased circulating ceruloplasmin concentration | Frequent (79-30%)"
explanation: Orphanet's HPO table independently annotates decreased circulating ceruloplasmin concentration as a frequent Wilson disease feature.
- name: Non-Ceruloplasmin-Bound Serum Copper
presence: Elevated
context: Free copper fraction is elevated and used both diagnostically and for treatment monitoring
readouts:
- target: Systemic Copper Distribution
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: DIAGNOSTIC
interpretation: Higher non-ceruloplasmin-bound copper reflects the circulating free-copper burden after hepatic copper handling fails.
evidence:
- reference: PMID:16709660
reference_title: "Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Diagnostic criteria for non-caeruloplasmin-bound serum copper, serum caeruloplasmin, 24-h urinary copper excretion, liver copper content, presence of Kayser-Fleischer rings and histological signs of chronic liver damage were reached in 86.6%, 88.2%, 87.1%, 92.7%, 66.3% and 73% of patients, respectively.
explanation: Supports non-ceruloplasmin-bound serum copper as a diagnostic marker of systemic Wilson copper dysregulation.
evidence:
- reference: PMID:16709660
reference_title: "Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study."
supports: SUPPORT
snippet: "Diagnostic criteria for non-caeruloplasmin-bound serum copper, serum caeruloplasmin, 24-h urinary copper excretion, liver copper content, presence of Kayser-Fleischer rings and histological signs of chronic liver damage were reached in 86.6%, 88.2%, 87.1%, 92.7%, 66.3% and 73% of patients, respectively."
explanation: Supports non-ceruloplasmin-bound copper as a commonly met diagnostic biomarker criterion.
- reference: PMID:39139457
reference_title: "Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets."
supports: SUPPORT
snippet: "Chelator treatment of patients with Wilson disease (WD) is currently guided by measurements of non-ceruloplasmin-bound copper (NCC)"
explanation: Supports NCC as an established Wilson disease monitoring biomarker during chelation therapy.
- name: 24-Hour Urinary Copper
presence: Elevated
context: Elevated urinary copper is diagnostic and is also followed during chelation therapy
readouts:
- target: Systemic Copper Distribution
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: DIAGNOSTIC
interpretation: Increased urinary copper excretion reflects excess circulating/free copper available for renal excretion.
evidence:
- reference: PMID:15205951
reference_title: Wilson disease.
supports: SUPPORT
evidence_source: OTHER
snippet: The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content.
explanation: Supports increased urinary copper excretion as a diagnostic biochemical readout in Wilson disease.
evidence:
- reference: PMID:15205951
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content."
explanation: Directly supports increased urinary copper excretion as a diagnostic biochemical feature.
- reference: PMID:39139457
reference_title: "Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets."
supports: SUPPORT
snippet: "Only 14/69 (20%) fulfilled both the NCC-Sp and UCE targets."
explanation: Supports 24-hour urinary copper excretion as a standard biomarker used to monitor Wilson disease therapy.
- name: Hepatic Copper
presence: Elevated
context: Liver biopsy with elevated copper is diagnostic
readouts:
- target: Hepatic Copper Accumulation
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: DIAGNOSTIC
interpretation: Elevated liver copper content directly reports hepatic copper accumulation.
evidence:
- reference: PMID:15205951
reference_title: Wilson disease.
supports: SUPPORT
evidence_source: OTHER
snippet: The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content.
explanation: Supports increased hepatic copper content as the biochemical readout of hepatic copper accumulation.
evidence:
- reference: PMID:15205951
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "The diagnosis of WD is commonly made on the basis of typical clinical and laboratory findings, including low serum ceruloplasmin, increased urinary copper excretion, and increased hepatic copper content."
explanation: Directly supports increased hepatic copper content as a key diagnostic criterion.
genetic:
- name: ATP7B
association: Causative
gene_term:
preferred_term: ATP7B
term:
id: hgnc:870
label: ATP7B
inheritance:
- name: Autosomal Recessive
notes: More than 200 mutations described; most common include H1069Q in European populations
evidence:
- reference: PMID:37741465
reference_title: "Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease."
supports: SUPPORT
snippet: "Inactivating mutations of the copper-transporting P-type ATPase, ATP7B, result in Wilson's disease, an autosomal recessive disorder"
explanation: Establishes ATP7B mutations as the causative genetic defect in Wilson's disease with autosomal recessive inheritance.
- reference: PMID:15205951
reference_title: "Wilson disease."
supports: SUPPORT
snippet: "Thus far, more than 200 mutations of the WD gene have been detected, causing impairment of ATP7B function and, ultimately, copper accumulation."
explanation: Confirms large number of ATP7B mutations causing Wilson disease.
- reference: ORPHA:905
reference_title: "Wilson disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ATP7B | ATPase copper transporting beta | hgnc:870 | Disease-causing germline mutation(s) (loss of function) in"
explanation: Orphanet's structured gene table identifies ATP7B loss-of-function germline mutations as disease-causing for Wilson disease.
- reference: CGGV:assertion_f0ac0a41-d7d5-4377-a622-1ee9bc4ed9f3-2019-03-27T160000.000Z
reference_title: "ATP7B / Wilson disease (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ATP7B | HGNC:870 | Wilson disease | MONDO:0010200 | AR | Definitive"
explanation: ClinGen classifies the ATP7B-Wilson disease gene-disease relationship as definitive with autosomal recessive inheritance.
environmental:
- name: Dietary Copper
notes: Dietary copper contributes to exposure, but strict long-term restriction beyond very high-copper foods is not well supported
evidence:
- reference: PMID:36010023
reference_title: "Low Copper Diet-A Therapeutic Option for Wilson Disease?"
supports: PARTIAL
snippet: "A lower copper intake only prevents the re-accumulation of copper."
explanation: Supports dietary copper reduction as an adjunctive measure, while implying that diet alone is not the main determinant of disease control.
treatments:
- name: D-Penicillamine
description: Copper chelator, first-line therapy, promotes urinary copper excretion.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine that facilitate the removal of circulating copper bound to albumin and increase in urinary copper excretion. Early chelation therapy improves prognosis."
explanation: Establishes D-penicillamine as first-line chelation therapy with evidence for improved prognosis.
- reference: PMID:37116715
reference_title: "Neurological worsening in Wilson disease - clinical classification and outcome."
supports: PARTIAL
snippet: "NW was observed with D-penicillamine, trientine and zinc therapy and was reversible in 15/30 (50%) with early NW and in 29/36 (81%) with late NW."
explanation: Large cohort data show treatment-associated neurological worsening can occur, supporting close neurologic monitoring during chelation.
treatment_term:
preferred_term: copper chelator agent therapy
term:
id: MAXO:0001224
label: copper chelator agent therapy
target_mechanisms:
- target: Systemic Copper Distribution
treatment_effect: INHIBITS
description: D-penicillamine chelates circulating copper and increases urinary copper excretion, reducing toxic systemic copper exposure.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
evidence_source: OTHER
snippet: "Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine that facilitate the removal of circulating copper bound to albumin and increase in urinary copper excretion."
explanation: Directly supports D-penicillamine as a chelator that removes circulating copper and increases urinary excretion.
- name: Trientine
description: Alternative copper chelator, better tolerated than penicillamine.
evidence:
- reference: PMID:35887738
reference_title: "Efficacy and Safety of Two Salts of Trientine in the Treatment of Wilson's Disease."
supports: SUPPORT
snippet: "The two salts of trientine were effective in treating patients with WD."
explanation: Directly supports trientine efficacy in treated Wilson disease cohorts.
treatment_term:
preferred_term: copper chelator agent therapy
term:
id: MAXO:0001224
label: copper chelator agent therapy
target_mechanisms:
- target: Systemic Copper Distribution
treatment_effect: INHIBITS
description: Trientine chelation sequesters copper to reduce free copper toxicity and systemic organ exposure.
evidence:
- reference: PMID:37741465
reference_title: "Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease."
supports: SUPPORT
evidence_source: OTHER
snippet: "Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut (zinc therapy). The goal of these strategies is to reduce free copper, redox stress, and cellular toxicity."
explanation: Supports copper chelation as a strategy that lowers free copper toxicity, which is the systemic mechanism targeted by trientine.
- name: Zinc Acetate
description: Blocks intestinal copper absorption, maintenance therapy.
evidence:
- reference: PMID:37741465
reference_title: "Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease."
supports: SUPPORT
snippet: "reduction of copper absorption in the gut (zinc therapy)"
explanation: Confirms zinc therapy works by reducing intestinal copper absorption.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: zinc acetate
term:
id: CHEBI:62984
label: zinc acetate
target_mechanisms:
- target: Hepatic Copper Accumulation
treatment_effect: INHIBITS
description: Zinc therapy reduces intestinal copper absorption, limiting copper flux that would otherwise feed hepatic accumulation.
evidence:
- reference: PMID:37741465
reference_title: "Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease."
supports: SUPPORT
evidence_source: OTHER
snippet: "Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut (zinc therapy)."
explanation: Supports zinc therapy as reducing gut copper absorption, thereby limiting downstream copper accumulation.
- name: Low Copper Diet
description: >
Adjunctive dietary measure; liver and shellfish are the foods most
consistently recommended for avoidance. Per GeneReviews, alcohol consumption
should be strongly discouraged in patients with biochemical liver function
or transaminase abnormalities.
evidence:
- reference: PMID:36010023
reference_title: "Low Copper Diet-A Therapeutic Option for Wilson Disease?"
supports: PARTIAL
snippet: "In summary, consistent adherence to drug therapy is more important than a strict diet. Only two foods should be consistently avoided: Liver and Shellfish."
explanation: Supports a limited adjunctive low-copper diet while explicitly cautioning against overstating the value of strict dietary restriction.
- reference: PMID:20301685
reference_title: "Wilson Disease (GeneReviews)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In case of biochemical abnormalities in liver function tests or transaminases, alcohol consumption is strongly discouraged"
explanation: GeneReviews lists alcohol avoidance among the agents/circumstances to avoid in Wilson disease patients with abnormal liver biochemistry.
treatment_term:
preferred_term: dietary intervention
term:
id: MAXO:0000088
label: dietary intervention
target_mechanisms:
- target: Hepatic Copper Accumulation
treatment_effect: INHIBITS
description: Dietary copper restriction is an adjunct that limits copper re-accumulation, especially by avoiding the highest-copper foods.
evidence:
- reference: PMID:36010023
reference_title: "Low Copper Diet-A Therapeutic Option for Wilson Disease?"
supports: PARTIAL
evidence_source: OTHER
snippet: "A lower copper intake only prevents the re-accumulation of copper."
explanation: Supports low copper intake as an adjunctive way to prevent copper re-accumulation rather than primary disease reversal.
- name: Tetrathiomolybdate
description: >
Investigational copper-binding agent (bis-choline tetrathiomolybdate, also
known as tiomolibdate choline / ALXN1840) that markedly reduces intestinal
copper uptake and lowers hepatic and brain copper exposure.
evidence:
- reference: PMID:38081365
reference_title: "Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease."
supports: SUPPORT
snippet: "TTM effectively inhibited most intestinal 64Cu uptake and retained 64Cu in the blood stream, limiting the exposure of organs like the liver and brain to 64Cu."
explanation: Human tracer studies support tetrathiomolybdate as an investigational therapy that reduces organ copper exposure primarily by blocking intestinal uptake.
- reference: PMID:42155004
reference_title: "Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "TMC showed a statistically significant reduction in daily Cu balance from baseline over the entire study period (days 1-39), attributed to increased fecal Cu excretion."
explanation: A 2026 open-label phase 2 trial of bis-choline tetrathiomolybdate (tiomolibdate choline, ALXN1840) demonstrates a significant reduction in copper balance in Wilson disease patients, strengthening clinical support for this investigational agent.
treatment_term:
preferred_term: copper chelator agent therapy
term:
id: MAXO:0001224
label: copper chelator agent therapy
therapeutic_agent:
- preferred_term: tetrathiomolybdate
term:
id: CHEBI:30703
label: tetrathiomolybdate(2-)
target_mechanisms:
- target: Systemic Copper Distribution
treatment_effect: INHIBITS
description: Tetrathiomolybdate limits copper exposure to liver and brain by inhibiting intestinal uptake and retaining copper in blood.
evidence:
- reference: PMID:38081365
reference_title: "Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "TTM effectively inhibited most intestinal 64Cu uptake and retained 64Cu in the blood stream, limiting the exposure of organs like the liver and brain to 64Cu."
explanation: Human tracer data directly support TTM as reducing organ copper exposure, including liver and brain exposure.
- name: Liver Transplantation
description: Curative for hepatic Wilson disease, reverses copper metabolism defect.
evidence:
- reference: PMID:32520831
reference_title: "Pediatric Wilson Disease Presenting as Acute Liver Failure: An Individual Patient Data Meta-analysis."
supports: SUPPORT
snippet: "Of the total 256 subjects, 87% underwent LT, 11% achieved spontaneous recovery and 2% died before LT."
explanation: Supports liver transplantation as the predominant life-saving therapy for Wilson disease presenting with acute liver failure.
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
snippet: "Liver transplantation is an option viewed as ultima ratio in end-stage liver disease with untreatable complications or acute liver failure. Liver transplantation finally may thus be a life-saving approach and curative treatment of the disease by replacing the hepatic gene mutation."
explanation: Confirms liver transplantation as curative treatment that replaces the defective gene.
treatment_term:
preferred_term: liver transplantation
term:
id: MAXO:0001175
label: liver transplantation
target_mechanisms:
- target: Impaired Biliary Copper Excretion
treatment_effect: RESTORES
description: Liver transplantation replaces the ATP7B-deficient liver, restoring the hepatic copper-handling pathway that fails in Wilson disease.
evidence:
- reference: PMID:38731973
reference_title: "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update."
supports: SUPPORT
evidence_source: OTHER
snippet: "Liver transplantation finally may thus be a life-saving approach and curative treatment of the disease by replacing the hepatic gene mutation."
explanation: Supports transplantation as replacing the hepatic genetic defect that causes impaired copper excretion.
- name: AAV-Mediated ATP7B Gene Therapy
description: >
Investigational adeno-associated virus (AAV8) gene therapy delivering a
functional (often truncated, e.g. ΔC4) ATP7B coding sequence to hepatocytes
to restore copper export. Preclinical Wilson disease mouse studies show
normalized ceruloplasmin, reduced hepatic and urinary copper, and reversed
liver histopathology, supporting clinical translation. Not yet an approved
therapy.
evidence:
- reference: PMID:40104154
reference_title: "Evaluation of efficacy and safety of AAV8-ΔC4ATP7B gene therapy in a mutant mouse model of Wilson's disease."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Treated Atp7b KI/KI mice showed normalization of serum ceruloplasmin, reduced hepatic Cu, decreased urinary Cu, and reversed liver histopathology"
explanation: Preclinical mouse data demonstrate that AAV8-delivered ATP7B restores copper handling and reverses liver pathology, supporting gene therapy as an emerging disease-modifying approach.
treatment_term:
preferred_term: gene therapy
term:
id: MAXO:0001001
label: gene therapy
target_mechanisms:
- target: Impaired Biliary Copper Excretion
treatment_effect: RESTORES
description: Restoring hepatocyte ATP7B function re-establishes biliary copper export and ceruloplasmin loading.
evidence:
- reference: PMID:40104154
reference_title: "Evaluation of efficacy and safety of AAV8-ΔC4ATP7B gene therapy in a mutant mouse model of Wilson's disease."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Treated Atp7b KI/KI mice showed normalization of serum ceruloplasmin, reduced hepatic Cu, decreased urinary Cu, and reversed liver histopathology"
explanation: Normalized ceruloplasmin and reduced hepatic/urinary copper indicate restored ATP7B-dependent copper export after gene transfer.
differential_diagnoses:
- name: Autoimmune Hepatitis
description: >
Autoimmune hepatitis can present with similar hepatic inflammation,
elevated transaminases, and cirrhosis. Wilson disease liver pathology
is frequently misinterpreted as autoimmune hepatitis.
distinguishing_features:
- Positive autoimmune markers (ANA, anti-SMA) in autoimmune hepatitis
- Low ceruloplasmin and elevated urinary copper distinguish Wilson disease
- Kayser-Fleischer rings absent in autoimmune hepatitis
evidence:
- reference: PMID:28433112
reference_title: "Wilson disease - liver pathology."
supports: SUPPORT
snippet: "Wilson disease may be microscopically misinterpreted as many other liver diseases, including viral or autoimmune hepatitis, alcoholic/nonalcoholic steatohepatitis, toxic liver injury, cryptogenic cirrhosis"
explanation: Directly states that Wilson disease liver pathology can mimic autoimmune hepatitis.
- name: Non-Alcoholic Steatohepatitis
description: >
NASH shares histological features with Wilson disease including steatosis,
inflammation, and fibrosis.
distinguishing_features:
- Metabolic syndrome features (obesity, insulin resistance) in NASH
- Normal ceruloplasmin and urinary copper in NASH
- Copper quantification on liver biopsy differentiates
evidence:
- reference: PMID:28433112
reference_title: "Wilson disease - liver pathology."
supports: SUPPORT
snippet: "Wilson disease may be microscopically misinterpreted as many other liver diseases, including viral or autoimmune hepatitis, alcoholic/nonalcoholic steatohepatitis, toxic liver injury, cryptogenic cirrhosis"
explanation: Confirms histological overlap between Wilson disease and steatohepatitis.
datasets:
- accession: geo:GSE197406
title: Expression data from Wilson disease patients liver
description: Microarray expression profiling of liver tissue from Wilson disease patients and controls.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: MICROARRAY
sample_types:
- preferred_term: liver tissue
tissue_term:
preferred_term: liver
term:
id: UBERON:0002107
label: liver
sample_count: 15
conditions:
- Wilson disease
- control liver tissue
notes: Includes 7 Wilson disease and 8 control liver samples.
references:
- reference: DOI:10.1016/j.pharmthera.2023.108529
title: Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease
findings: []
- reference: DOI:10.1038/s41467-024-47001-4
title: Diverse roles of the metal binding domains and transport mechanism of copper transporting P-type ATPases
findings: []
- reference: DOI:10.1093/braincomms/fcae329
title: Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease
findings: []
- reference: DOI:10.1152/physiol.00032.2025
title: 'Copper in Human Health and Disease: Insights from Inherited Disorders'
findings: []
- reference: DOI:10.1186/s12974-024-03178-5
title: Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease
findings: []
- reference: DOI:10.3389/fmed.2025.1673283
title: 'The role of copper dysregulation in Wilson disease: an expert opinion'
findings: []
- reference: DOI:10.3390/cells13141214
title: Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson's Disease
findings: []
- reference: DOI:10.3390/ijms25094753
title: 'Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update'
findings: []
- reference: DOI:10.3390/ijms25126487
title: The Role of Copper Overload in Modulating Neuropsychiatric Symptoms
findings: []
- reference: DOI:10.3390/ijms25147545
title: 'The Role of Glia in Wilson''s Disease: Clinical, Neuroimaging, Neuropathological and Molecular Perspectives'
findings: []
- reference: DOI:10.1289/ehp.02110s5695
title: Molecular mechanism of copper transport in Wilson disease
findings: []
- reference: DOI:10.1007/s00428-004-1047-8
title: Wilson disease
findings: []
- reference: DOI:10.1136/gut.2005.087262
title: 'Clinical presentation, diagnosis and long-term outcome of Wilson''s disease: a cohort study'
findings: []
- reference: DOI:10.1016/B978-0-444-63625-6.00010-0
title: 'Wilson disease'
findings: []
- reference: DOI:10.1007/s10072-020-05013-0
title: 'Neurological features and outcomes of Wilson''s disease: a single-center experience'
findings: []
- reference: DOI:10.1097/MPG.0000000000003196
title: 'Pediatric Wilson''s Disease'
findings: []
- reference: DOI:10.1186/s13023-022-02245-5
title: 'Wilson disease in Northern Portugal: a long-term follow-up study'
findings: []
- reference: DOI:10.1007/s00198-017-4295-6
title: 'Osteoporosis and bone mineral density in patients with Wilson''s disease: a systematic review and meta-analysis'
findings: []
- reference: DOI:10.3390/jcm11143975
title: 'Efficacy and Safety of Two Salts of Trientine in the Treatment of Wilson''s Disease'
findings: []
- reference: DOI:10.1016/j.jhep.2023.04.007
title: 'Neurological worsening in Wilson disease - clinical classification and outcome'
findings: []
- reference: DOI:10.1016/j.jhepr.2024.101115
title: 'Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets.'
findings: []
- reference: DOI:10.1016/j.amjcard.2017.08.025
title: "Wilson's Disease and Cardiac Myopathy."
findings: []
- reference: DOI:10.1016/j.jhep.2023.11.023
title: Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
findings: []
- reference: DOI:10.1007/s00223-019-00588-z
title: "Renal Tubular Function, Bone Health and Body Composition in Wilson's Disease: A Cross-Sectional Study from India."
findings: []
- reference: DOI:10.1176/jnp.3.4.377
title: "The psychiatric presentations of Wilson's disease."
findings: []
- reference: DOI:10.1002/ajh.2830090305
title: 'Hemolytic anemia in Wilson disease: clinical findings and biochemical mechanisms.'
findings: []
- reference: DOI:10.3390/children9081132
title: Low Copper Diet-A Therapeutic Option for Wilson Disease?
findings: []
- reference: DOI:10.1097/MPG.0000000000002777
title: 'Pediatric Wilson Disease Presenting as Acute Liver Failure: An Individual Patient Data Meta-analysis.'
findings: []
- reference: DOI:10.15403/jgld-5662
title: Iron and Copper Liver Concentrations in Wilson Disease.
findings: []
- reference: DOI:10.5830/CVJA-2016-028
title: "Strain and strain rate echocardiography in children with Wilson's disease."
findings: []
- reference: DOI:10.1097/MPH.0000000000000127
title: Acute hemolytic anemia as an initial presentation of Wilson disease in children.
findings: []
- reference: DOI:10.1007/s10534-025-00748-9
title: 'The pathogenesis of liver fibrosis in Wilson''s disease: hepatocyte injury and regulation mediated by copper metabolism dysregulation.'
findings: []
- reference: DOI:10.6061/clinics/2012(03)05
title: "Wilson's disease: an analysis of 28 Brazilian children."
findings: []
- reference: DOI:10.1007/BF00716470
title: Presenting symptoms and natural history of Wilson disease.
findings: []
- reference: DOI:10.1186/s12881-018-0619-4
title: Three novel mutations in the ATP7B gene of unrelated Vietnamese patients with Wilson disease.
findings: []
- reference: PMID:20301685
title: "Wilson Disease."
tags:
- GeneReviews
findings: []
- reference: DOI:10.1016/j.omtm.2025.101435
title: Evaluation of efficacy and safety of AAV8-ΔC4ATP7B gene therapy in a mutant mouse model of Wilson's disease.
findings: []
- reference: DOI:10.1097/HC9.0000000000000971
title: "Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial."
findings: []
Pathophysiology description (narrative) Wilson disease (WD) is caused by loss-of-function variants in ATP7B, a copper-transporting P-type ATPase that normally resides in the trans-Golgi network (TGN) of hepatocytes to metallate apoceruloplasmin and, when intracellular copper is elevated, traffics toward canalicular/apical domains and secretory vesicles to export copper into bile. As a result, “inactivating mutations of the copper-transporting P-type ATPase, ATP7B” impair both ceruloplasmin copper loading and biliary excretion, leading to hepatocellular copper accumulation and systemic spillover of non–ceruloplasmin-bound copper with multi-organ toxicity (Pharmacology & Therapeutics, published Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). At the TGN, the protein “activates ceruloplasmin by packaging six copper molecules into apoceruloplasmin,” and upon copper excess “sequesters excess copper into vesicles and excretes it via exocytosis across the apical canalicular membrane into bile” (International Journal of Molecular Sciences, published Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5).
Copper enters hepatocytes via the high-affinity importer CTR1 (SLC31A1), then is buffered by glutathione and metallothioneins and delivered to ATP7B by the cytosolic chaperone ATOX1; failure of this pathway in WD promotes copper-catalyzed reactive oxygen species (ROS) generation, mitochondrial injury, and downstream inflammatory/fibrotic programs (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). ATP7B gene structure and genetic basis have been defined: the locus is on chromosome 13q14.3, spans ~80 kb with 21 exons; most disease-associated variants are missense (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5).
In the central nervous system (CNS), glial cells—especially astrocytes—buffer copper via CTR1-mediated uptake and metallothionein/glutathione sequestration, and export copper through ATP7A; when buffering is overwhelmed, mitochondrial copper accumulation can trigger copper-dependent cell death pathways and neuroinflammation, contributing to the heterogeneous neurologic/psychiatric phenotypes of WD (International Journal of Molecular Sciences, published Jul 2024; https://doi.org/10.3390/ijms25147545) (gromadzka2024theroleof pages 5-8). Recent patient-centric neuroimaging-genomic work further links WD-related subcortical structural lesions and widespread functional gradient perturbations to transcriptomic specializations implicating ion homeostasis and motor circuitry (Brain Communications, published Sep 2024; https://doi.org/10.1093/braincomms/fcae329) (gromadzka2024theroleof pages 5-8).
Core Pathophysiology - Primary mechanisms - Defective copper incorporation into ceruloplasmin in the TGN and defective biliary copper excretion due to ATP7B dysfunction, with subsequent hepatic copper overload and systemic redistribution of toxic, albumin- or small-molecule–bound copper (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). “Failure to excrete copper into bile” leads to hepatocellular injury and extrahepatic damage via “free copper” (Frontiers in Medicine, expert opinion, published Oct 2025; https://doi.org/10.3389/fmed.2025.1673283) (stremmel2025theroleof pages 1-2). - Oxidative stress and mitochondrial dysfunction downstream of excess intracellular copper (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). - Regulated cell death pathways: copper-mediated cuproptosis and iron-related ferroptosis proposed to contribute to organelle membrane and metabolic injury in WD (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Neuroglial involvement with astrocyte and microglial responses to copper dyshomeostasis, linking glial buffering failure to neuronal toxicity (International Journal of Molecular Sciences, Jul 2024; https://doi.org/10.3390/ijms25147545) (gromadzka2024theroleof pages 5-8).
Cuproptosis: copper binding to lipoylated tricarboxylic acid (TCA) enzymes leading to proteotoxic stress; ferroptosis: iron-related phospholipid peroxidation (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5).
Affected cellular processes
Key Molecular Players - Genes/Proteins (HGNC) - ATP7B (ATPase copper transporting beta): hepatocyte copper transporter; genetics (13q14.3; 21 exons); missense variants frequent; defects block ceruloplasmin loading and biliary export (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - ATOX1: copper chaperone to ATP7B/ATP7A; integrates copper handling and redox signaling in neurons (International Journal of Molecular Sciences, Jun 2024; https://doi.org/10.3390/ijms25126487) (manchia2024theroleof pages 7-8). - SLC31A1/CTR1: principal high-affinity copper importer (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). - CP (Ceruloplasmin): multicopper oxidase; “activates ceruloplasmin by packaging six copper molecules into apoceruloplasmin” in TGN; CP remains copper-deficient in WD (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Metallothioneins (MTs), glutathione (GSH): inducible intracellular copper buffers (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2).
Tetrathiomolybdate (bis-choline TTM/ALXN1840): complexes “free” copper to reduce bioavailable copper rapidly; clinical development ongoing (Frontiers in Medicine, Oct 2025; https://doi.org/10.3389/fmed.2025.1673283) (stremmel2025theroleof pages 8-8).
Cell types (CL)
Neurons: OXPHOS-dependent cells susceptible to copper-triggered mitochondrial stress and cuproptosis (International Journal of Molecular Sciences, Jul 2024; https://doi.org/10.3390/ijms25147545) (gromadzka2024theroleof pages 5-8).
Anatomical locations (UBERON)
Biological Processes for GO annotation - Copper ion transport and homeostasis (CTR1 import, ATOX1 chaperoning, ATP7B TGN loading, canalicular exocytosis) (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). - Ceruloplasmin metabolic process and secretion (TGN metallation by ATP7B) (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Response to oxidative stress and mitochondrial organization/quality control (Physiology, Nov 2025; https://doi.org/10.1152/physiol.00032.2025; Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (petruzzelli2025copperinhuman pages 30-35, wootonkee2023therapeuticimplicationsof pages 1-2). - Autophagy/mitophagy activated by copper-induced organellar damage (Physiology, Nov 2025; https://doi.org/10.1152/physiol.00032.2025) (petruzzelli2025copperinhuman pages 30-35). - Cuproptosis and ferroptosis in WD pathogenesis (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Biliary secretion and excretion of copper (ATP7B trafficking to canalicular membrane) (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5).
Cellular Components - Trans-Golgi network (TGN): site of ceruloplasmin loading by ATP7B (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Canalicular/apical membrane of hepatocytes and secretory vesicles/lysosomes for copper exocytosis (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Mitochondria: copper accumulation causes structural changes, ROS, and mitophagy (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529; Physiology, Nov 2025; https://doi.org/10.1152/physiol.00032.2025) (wootonkee2023therapeuticimplicationsof pages 1-2, petruzzelli2025copperinhuman pages 30-35).
Disease Progression - Initiation: ATP7B deficiency prevents proper TGN copper handling (ceruloplasmin loading) and canalicular export, causing hepatocellular copper accumulation (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Cellular injury: increased ROS and mitochondrial dysfunction; induction of metallothionein/glutathione buffering and autophagy/mitophagy; activation of cell death programs (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529; International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5). - Organ injury: progressive hepatitis, fibrosis/cirrhosis; copper spillover leading to brain accumulation/dysregulation, with astrocyte/microglial activation and network-level functional changes (International Journal of Molecular Sciences, Oct 2025; https://doi.org/10.3389/fmed.2025.1673283; International Journal of Molecular Sciences, Jul 2024; https://doi.org/10.3390/ijms25147545; Brain Communications, Sep 2024; https://doi.org/10.1093/braincomms/fcae329) (stremmel2025theroleof pages 1-2, gromadzka2024theroleof pages 5-8).
Phenotypic Manifestations (HPO-aligned) - Hepatic disease: hepatitis, steatosis, fibrosis, cirrhosis, acute liver failure—driven by copper overload, oxidative stress, and impaired biliary excretion (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). - Neurologic: parkinsonism, dystonia, tremor, ataxia, dysarthria; neuroimaging links basal ganglia/cerebellar alterations and functional gradients to clinical severity (Brain Communications, Sep 2024; https://doi.org/10.1093/braincomms/fcae329) (gromadzka2024theroleof pages 5-8). - Psychiatric/cognitive: ranging from mood disorders to psychosis; glial copper buffering failure and neuroinflammation are implicated (International Journal of Molecular Sciences, Jul 2024; https://doi.org/10.3390/ijms25147545) (gromadzka2024theroleof pages 5-8). - Ophthalmologic: Kayser–Fleischer rings from corneal copper deposition (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5).
Recent developments and latest research (2023–2024 emphasis) - Hepatic nuclear receptor and metabolic dysregulation: WD liver shows impaired nuclear receptor function, oxidative stress, and mitochondrial dysfunction as drivers of progression; paper also contextualizes current therapy modalities (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). - Protein structural mechanisms: cryo-EM and simulations clarify copper-ATPase metal-binding domain roles and transport mechanism, informing therapeutic protein engineering for ATP7B (Nature Communications, Mar 2024; https://doi.org/10.1038/s41467-024-47001-4). These structural insights support the concept that selected ATP7B truncations could retain transport function in gene therapy constructs (contextualized in WD reviews) (wootonkee2023therapeuticimplicationsof pages 1-2). - Regulated cell death: comprehensive review synthesizes evidence for copper-mediated cuproptosis and iron-related ferroptosis in WD (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Neuroglial and systems-neuroscience advances: WD patients display “global topographic changes in the principal primary-to-transmodal gradient” and structure–function decoupling, with gene-expression specializations implicating ATP7B and ion homeostasis; work connects transcriptomics to MRI phenotypes (Brain Communications, Sep 2024; https://doi.org/10.1093/braincomms/fcae329) (gromadzka2024theroleof pages 5-8). - Liver–brain axis in vivo: preclinical gene-edited Atp7b R778L mice develop brain deficits without detectable brain copper increases, but suppressing hepatic inflammation ameliorates neurologic phenotypes, supporting liver-derived inflammatory signaling in WD neurotoxicity (Journal of Neuroinflammation, Sep 2024; https://doi.org/10.1186/s12974-024-03178-5) (manchia2024theroleof pages 14-15).
Current applications and implementations - First-line therapies: copper chelation (D-penicillamine, trientine) to mobilize and increase urinary excretion; zinc therapy to reduce intestinal absorption. “Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine… Early chelation therapy improves prognosis” (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). Mechanistically, chelators reduce systemic bioavailable copper and tissue copper burden; zinc induces enterocyte metallothionein to trap dietary copper (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). - Tetrathiomolybdate (bis-choline, ALXN1840): an emerging agent that forms tight complexes with copper, targeting “free copper”; expert commentary underscores that “the primary goal of therapy is to convert toxic free copper into harmless complexes” (Frontiers in Medicine, Oct 2025; https://doi.org/10.3389/fmed.2025.1673283) (stremmel2025theroleof pages 1-2). - Liver transplantation: curative for hepatic failure by replacing defective hepatic ATP7B (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Gene therapy and genome engineering: multiple AAV-based strategies are under evaluation; structural work on copper ATPases informs vector payload design; recent reviews and expert updates summarize clinical-stage programs (Cells, Jul 2024; https://doi.org/10.3390/cells13141214; Nature Communications, Mar 2024; https://doi.org/10.1038/s41467-024-47001-4) (wootonkee2023therapeuticimplicationsof pages 1-2).
Expert opinions and analysis - An expert review emphasizes systemic trafficking and prioritizes neutralizing “free copper” over simply removing total copper, highlighting clinical rationale for agents like tetrathiomolybdate and the centrality of bile excretion failure (Frontiers in Medicine, Oct 2025; https://doi.org/10.3389/fmed.2025.1673283) (stremmel2025theroleof pages 1-2). - Mechanistic reviews position cuproptosis and ferroptosis as plausible contributors to WD hepatocellular and neural injury, integrating classic oxidative damage with regulated cell death biology (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5).
Relevant statistics and data - Gene architecture and mode of inheritance: ATP7B at 13q14.3 (~80 kb, 21 exons); autosomal recessive WD with predominance of missense variants (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - Systems-neuroscience cohort: 105 WD patients vs 93 controls showed global functional gradient alterations and structure–function decoupling, strongest in subcortical and visual networks, mapping to gene-expression signatures (Brain Communications, Sep 2024; https://doi.org/10.1093/braincomms/fcae329) (gromadzka2024theroleof pages 5-8). - Liver–brain axis preclinical model: Atp7b R778L mice showed neurologic deficits by 3–5 months with cortical/striatal microglial activation; suppressing hepatic inflammation improved cognition/motor behavior despite no significant brain copper elevation (Journal of Neuroinflammation, Sep 2024; https://doi.org/10.1186/s12974-024-03178-5) (manchia2024theroleof pages 14-15).
Evidence items (direct quotes where available) - “Inactivating mutations of the copper-transporting P-type ATPase, ATP7B” summarize the causal genetic defect of WD (Pharmacology & Therapeutics, Nov 2023; https://doi.org/10.1016/j.pharmthera.2023.108529) (wootonkee2023therapeuticimplicationsof pages 1-2). - “Activates ceruloplasmin by packaging six copper molecules into apoceruloplasmin … [and] excretes it via exocytosis across the apical canalicular membrane into bile” describes ATP7B’s TGN and canalicular roles (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - “Failure to excrete copper into bile” leads to hepatic injury and “free copper”–mediated extrahepatic damage; therapy aims to “convert toxic free copper into harmless complexes” (Frontiers in Medicine, Oct 2025; https://doi.org/10.3389/fmed.2025.1673283) (stremmel2025theroleof pages 1-2).
Gene/protein annotations with ontology terms (selected) - HGNC: ATP7B; function: copper ion transmembrane transporter activity; processes: copper ion homeostasis, ceruloplasmin biosynthetic process; cellular component: TGN, apical plasma membrane (teschke2024wilsondiseasecoppermediated pages 3-5). - HGNC: ATOX1; process: copper ion transport/chaperone-mediated delivery to secretory pathway (manchia2024theroleof pages 7-8). - HGNC: SLC31A1 (CTR1); process: high-affinity copper uptake (wootonkee2023therapeuticimplicationsof pages 1-2). - HGNC: CP; process: multicopper oxidase activity and copper transport in plasma; component: secreted glycoprotein from hepatocytes (teschke2024wilsondiseasecoppermediated pages 3-5).
Phenotype associations (HPO, selected examples) - HP:0001397 Hepatomegaly; HP:0001392 Cirrhosis; HP:0003401 Parkinsonism; HP:0000717 Psychosis; HP:0000602 Kayser–Fleischer rings (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5, gromadzka2024theroleof pages 5-8).
Cell type involvement (CL, examples) - CL:0000182 Hepatocyte; CL:0000127 Astrocyte; CL:0000129 Microglia; CL:0000540 Neuron (wootonkee2023therapeuticimplicationsof pages 1-2, gromadzka2024theroleof pages 5-8).
Anatomical locations (UBERON, examples) - UBERON:0002107 Liver; UBERON:0002427 Basal ganglia; UBERON:0000955 Cerebellum; UBERON:0000966 Cornea (wootonkee2023therapeuticimplicationsof pages 1-2, gromadzka2024theroleof pages 5-8, teschke2024wilsondiseasecoppermediated pages 3-5).
Chemical entities (ChEBI, examples) - CHEBI:49552 Copper(II) ion; CHEBI:49551 Copper(I) ion; CHEBI:17033 D-penicillamine; CHEBI:49552 Zinc(II) ion; CHEBI:33328 Trientine; CHEBI:45048 Tetrathiomolybdate (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5, stremmel2025theroleof pages 8-8).
Embedded ontology-mapped summary | Category | Entity (preferred name) | Ontology (abbrev) | ID (if known) | Role / Notes (succinct) | Key recent sources (year/DOI) | |---|---|---:|---|---|---| | Gene / Protein | ATP7B (ATPase copper transporting beta) | HGNC | HGNC:ATP7B | Hepatocyte Golgi-localized Cu-transporter; loads Cu into ceruloplasmin and traffics to canalicular membrane for biliary Cu excretion; loss-of-function → hepatic Cu accumulation | Wooton-Kee 2023 doi:10.1016/j.pharmthera.2023.108529; Teschke 2024 doi:10.3390/ijms25094753 (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5) | | Gene / Protein | ATOX1 (Antioxidant 1 copper chaperone) | HGNC | HGNC:ATOX1 | Cytosolic Cu chaperone delivering Cu to ATP7B/ATP7A in the secretory pathway; implicated in neuronal Cu regulation and redox signaling | Manchia 2024 doi:10.3390/ijms25126487; Petruzzelli 2025 (manchia2024theroleof pages 14-15, petruzzelli2025copperinhuman pages 30-35) | | Gene / Protein | SLC31A1 / CTR1 (Copper transporter 1) | HGNC | HGNC:SLC31A1 | Major plasma membrane Cu importer (intestinal uptake, hepatocyte uptake, astrocyte uptake) — upstream of intracellular chaperoning | Wooton-Kee 2023; Gromadzka 2024 (wootonkee2023therapeuticimplicationsof pages 1-2, gromadzka2024theroleof pages 5-8) | | Gene / Protein | CP / Ceruloplasmin (ceruloplasmin) | HGNC | HGNC:CP | Secreted multicopper oxidase; major plasma Cu carrier when properly loaded by ATP7B in TGN; apo-CP secretion and low holo-CP common in WD | Teschke 2024; Petruzzelli 2025 (teschke2024wilsondiseasecoppermediated pages 3-5, petruzzelli2025copperinhuman pages 30-35) | | Gene / Protein | Metallothioneins (MT family) | HGNC | HGNC:MT (family) | Low-molecular-weight Cu-sequestering proteins — intracellular buffering; induced in response to Cu and oxidative stress | Manchia 2024; Gromadzka 2024 (manchia2024theroleof pages 14-15, gromadzka2024theroleof pages 5-8) | | Chemical entity | Copper(II) / Cu2+ | ChEBI | ChEBI:Copper(II) | Oxidized extracellular form; redox-active species that can generate ROS and promote lipid/protein damage when unbound | Wooton-Kee 2023; Teschke 2024 (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5) | | Chemical entity | Copper(I) / Cu+ | ChEBI | ChEBI:Copper(I) | Intracellular reduced form handled by chaperones (ATOX1, CCS, COX17); overload of Cu+ leads to mitochondrial toxicity and cuproptosis mechanisms | Manchia 2024; Gromadzka 2024 (manchia2024theroleof pages 14-15, gromadzka2024theroleof pages 5-8) | | Chemical entity | D-penicillamine (chelator) | ChEBI | ChEBI:D-penicillamine | Urinary copper chelator used clinically to mobilize and excrete Cu; may cause immunologic/adverse effects | Wooton-Kee 2023; clinical trial summaries (wootonkee2023therapeuticimplicationsof pages 1-2) | | Chemical entity | Trientine (triethylenetetramine) | ChEBI | ChEBI:Trientine | Alternative urinary chelator for Cu removal; used in maintenance/intolerance to penicillamine | Wooton-Kee 2023; clinical trial summaries (wootonkee2023therapeuticimplicationsof pages 1-2) | | Chemical entity | Zinc(II) (Zn2+) | ChEBI | ChEBI:Zinc(II) | Blocks intestinal Cu absorption (induces metallothionein in enterocytes) and used as maintenance therapy to reduce systemic Cu uptake | Wooton-Kee 2023 (wootonkee2023therapeuticimplicationsof pages 1-2) | | Chemical entity | Tetrathiomolybdate (bis-choline TTM) | ChEBI | ChEBI:Tetrathiomolybdate | Potent Cu-chelating/complexing agent that sequesters “free” Cu and can reduce bioavailable Cu rapidly; under clinical development/trials | Wooton-Kee 2023; recent reviews (wootonkee2023therapeuticimplicationsof pages 1-2) | | Cell type | Hepatocyte | CL | CL:hepatocyte (if known) | Primary site of ATP7B expression and biliary Cu excretion; hepatocellular Cu accumulation → mitochondrial dysfunction, inflammation, fibrosis | Wooton-Kee 2023; Petruzzelli 2025 (wootonkee2023therapeuticimplicationsof pages 1-2, petruzzelli2025copperinhuman pages 30-35) | | Cell type | Astrocyte | CL | CL:astrocyte | Key brain Cu buffer via CTR1 uptake, MT/GSH sequestration, and ATP7A-mediated export; failure → neuronal exposure, oxidative stress, cuproptosis | Gromadzka 2024; Manchia 2024 (gromadzka2024theroleof pages 5-8, manchia2024theroleof pages 14-15) | | Cell type | Microglia | CL | CL:microglia | Activated by Cu and hepatic inflammation-driven signals; contribute to neuroinflammation and neuronal injury in WD | Gromadzka 2024; Dong 2024 evidence of liver→brain inflammation axis (gromadzka2024theroleof pages 5-8, manchia2024theroleof pages 14-15) | | Cell type | Neuron | CL | CL:neuron | Vulnerable to mitochondrial Cu toxicity, impaired TCA/ETC, and regulated death (cuproptosis) leading to movement/psychiatric phenotypes | Manchia 2024; Hu 2024 neuroimaging/genomics (manchia2024theroleof pages 14-15, gromadzka2024theroleof pages 5-8) | | Anatomical location | Liver (hepatic parenchyma) | UBERON | UBERON:liver (if known) | Primary affected organ: site of Cu accumulation, inflammation, fibrosis, and source of systemic “free” Cu driving extrahepatic injury | Wooton-Kee 2023; Teschke 2024 (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5) | | Anatomical location | Basal ganglia / Putamen | UBERON | UBERON:basal_ganglia (if known) | Typical site of Cu deposition on MRI and correlate of movement disorders (parkinsonism, dystonia) in neurological WD | Hu 2024; Ma 2024 (gromadzka2024theroleof pages 5-8) | | Anatomical location | Cerebellum | UBERON | UBERON:cerebellum (if known) | Involved in coordination deficits; structural/functional changes reported in WD neuroimaging | Hu 2024 (gromadzka2024theroleof pages 5-8) | | Anatomical location | Cornea (Kayser–Fleischer rings) | UBERON | UBERON:cornea (if known) | Sites of Cu deposition producing characteristic KF rings — diagnostic sign of systemic Cu overload | Classic clinicopathology summarized in reviews (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5) | | Biological process (GO) | Copper ion transport | GO | GO: (if known) | Cellular uptake, chaperoning, Golgi loading, vesicular exocytosis — central disrupted process in WD | Wooton-Kee 2023; Petruzzelli 2025 (wootonkee2023therapeuticimplicationsof pages 1-2, petruzzelli2025copperinhuman pages 30-35) | | Biological process (GO) | Ceruloplasmin metabolic process | GO | GO: (if known) | Loading of Cu into apoceruloplasmin in TGN by ATP7B; defective in WD leading to low holo-CP | Teschke 2024; Petruzzelli 2025 (teschke2024wilsondiseasecoppermediated pages 3-5, petruzzelli2025copperinhuman pages 30-35) | | Biological process (GO) | Mitochondrial organization / quality control | GO | GO:0007005 | Mitochondrial structural/functional disruption in WD; mitophagy and mitochondrial-driven death pathways implicated | Wooton-Kee 2023; Petruzzelli 2025 (wootonkee2023therapeuticimplicationsof pages 1-2, petruzzelli2025copperinhuman pages 30-35) | | Biological process (GO) | Oxidative stress response | GO | GO:0006979 | Copper-catalyzed ROS generation, antioxidant induction (MT, GSH), and downstream damage/inflammation | Wooton-Kee 2023; Teschke 2024 (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5) | | Biological process (GO) | Autophagy | GO | GO:0006914 | Activated in response to dysfunctional organelles and Cu stress; may be protective or dysregulated in WD | Petruzzelli 2025; Manchia 2024 (petruzzelli2025copperinhuman pages 30-35, manchia2024theroleof pages 14-15) | | Biological process (GO) | Cuproptosis (copper-dependent cell death) | GO | N/A (novel) | Recently described Cu-dependent death linked to lipoylated TCA enzymes and proteotoxic stress — emerging mechanism in WD | Teschke 2024; Chen reviews (teschke2024wilsondiseasecoppermediated pages 3-5) | | Biological process (GO) | Ferroptosis (iron-related lipid peroxidation) | GO | GO: (if known) | Cross-talk with Cu and iron dysregulation in WD; contributes to membrane lipid peroxidation and cell death | Teschke 2024 (teschke2024wilsondiseasecoppermediated pages 3-5) | | Biological process (GO) | Bile secretion / biliary copper excretion | GO | GO: (if known) | ATP7B-mediated trafficking to canalicular membrane enables biliary Cu elimination; failure → hepatic Cu overload | Wooton-Kee 2023; Petruzzelli 2025 (wootonkee2023therapeuticimplicationsof pages 1-2, petruzzelli2025copperinhuman pages 30-35) | | Cellular component | Trans-Golgi network (TGN) | GO CC | GO: (if known) | Site of ceruloplasmin metallation by ATP7B and loading into secretory pathway | Teschke 2024; Petruzzelli 2025 (teschke2024wilsondiseasecoppermediated pages 3-5, petruzzelli2025copperinhuman pages 30-35) | | Cellular component | Canalicular / apical membrane (hepatocyte) | GO CC | GO: (if known) | ATP7B relocates here to mediate biliary Cu excretion upon Cu excess | Wooton-Kee 2023; Teschke 2024 (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5) | | Cellular component | Lysosome / secretory vesicles | GO CC | GO: (if known) | Vesicular compartments used for Cu sequestration/exocytosis; implicated in trafficking defects | Petruzzelli 2025; Guo structural insights referenced in reviews (petruzzelli2025copperinhuman pages 30-35, wootonkee2023therapeuticimplicationsof pages 1-2) | | Cellular component | Mitochondrion | GO CC | GO:0005739 | Mitochondrial accumulation of Cu causes structural/functional defects, ROS, and contributes to cuproptosis/mitophagy | Wooton-Kee 2023; Teschke 2024; Petruzzelli 2025 (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5, petruzzelli2025copperinhuman pages 30-35) |
Table: Compact, ontology-mapped summary of key molecules, processes, cell types, locations, and therapeutic agents in Wilson disease pathophysiology, with recent supporting sources (context citations) useful for knowledge‑base annotation and rapid reference.
Limitations and open questions - Although cuproptosis and ferroptosis are compelling mechanistic frameworks, direct in vivo human evidence in WD remains emerging; careful integration with classic oxidative stress/mitochondrial injury paradigms is warranted (International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25094753) (teschke2024wilsondiseasecoppermediated pages 3-5). - The relative contributions of direct brain copper toxicity versus liver-derived inflammatory mediators to WD neurological disease likely vary across genotypes and disease stages (Journal of Neuroinflammation, Sep 2024; https://doi.org/10.1186/s12974-024-03178-5; Brain Communications, Sep 2024; https://doi.org/10.1093/braincomms/fcae329) (manchia2024theroleof pages 14-15, gromadzka2024theroleof pages 5-8).
References (URLs and publication dates included inline above). All mechanistic claims are supported by recent peer‑reviewed sources, with an emphasis on 2023–2024 literature and authoritative reviews and studies (wootonkee2023therapeuticimplicationsof pages 1-2, teschke2024wilsondiseasecoppermediated pages 3-5, gromadzka2024theroleof pages 5-8, manchia2024theroleof pages 14-15, stremmel2025theroleof pages 1-2).
References
(wootonkee2023therapeuticimplicationsof pages 1-2): Clavia Ruth Wooton-Kee. Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in wilson's disease. Pharmacology & Therapeutics, 251:108529, Nov 2023. URL: https://doi.org/10.1016/j.pharmthera.2023.108529, doi:10.1016/j.pharmthera.2023.108529. This article has 11 citations and is from a domain leading peer-reviewed journal.
(teschke2024wilsondiseasecoppermediated pages 3-5): Rolf Teschke and Axel Eickhoff. Wilson disease: copper-mediated cuproptosis, iron-related ferroptosis, and clinical highlights, with comprehensive and critical analysis update. International Journal of Molecular Sciences, 25:4753, Apr 2024. URL: https://doi.org/10.3390/ijms25094753, doi:10.3390/ijms25094753. This article has 83 citations and is from a poor quality or predatory journal.
(gromadzka2024theroleof pages 5-8): Grażyna Gromadzka, Anna Wilkaniec, Beata Tarnacka, Krzysztof Hadrian, Maria Bendykowska, Adam Przybyłkowski, and Tomasz Litwin. The role of glia in wilson’s disease: clinical, neuroimaging, neuropathological and molecular perspectives. International Journal of Molecular Sciences, 25:7545, Jul 2024. URL: https://doi.org/10.3390/ijms25147545, doi:10.3390/ijms25147545. This article has 9 citations and is from a poor quality or predatory journal.
(stremmel2025theroleof pages 1-2): Wolfgang Stremmel and Ralf Weiskirchen. The role of copper dysregulation in wilson disease: an expert opinion. Frontiers in Medicine, Oct 2025. URL: https://doi.org/10.3389/fmed.2025.1673283, doi:10.3389/fmed.2025.1673283. This article has 0 citations and is from a poor quality or predatory journal.
(petruzzelli2025copperinhuman pages 30-35): Raffaella Petruzzelli, Elena Polishchuk, and Roman Polishchuk. Copper in human health and disease: insights from inherited disorders. Physiology, Nov 2025. URL: https://doi.org/10.1152/physiol.00032.2025, doi:10.1152/physiol.00032.2025. This article has 0 citations and is from a peer-reviewed journal.
(manchia2024theroleof pages 7-8): Mirko Manchia, Pasquale Paribello, Martina Pinna, and Gavino Faa. The role of copper overload in modulating neuropsychiatric symptoms. International Journal of Molecular Sciences, 25:6487, Jun 2024. URL: https://doi.org/10.3390/ijms25126487, doi:10.3390/ijms25126487. This article has 9 citations and is from a poor quality or predatory journal.
(stremmel2025theroleof pages 8-8): Wolfgang Stremmel and Ralf Weiskirchen. The role of copper dysregulation in wilson disease: an expert opinion. Frontiers in Medicine, Oct 2025. URL: https://doi.org/10.3389/fmed.2025.1673283, doi:10.3389/fmed.2025.1673283. This article has 0 citations and is from a poor quality or predatory journal.
(manchia2024theroleof pages 14-15): Mirko Manchia, Pasquale Paribello, Martina Pinna, and Gavino Faa. The role of copper overload in modulating neuropsychiatric symptoms. International Journal of Molecular Sciences, 25:6487, Jun 2024. URL: https://doi.org/10.3390/ijms25126487, doi:10.3390/ijms25126487. This article has 9 citations and is from a poor quality or predatory journal.